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Functions for Murine Norovirus Protein NS1/2 in Mice and Cells  
by 
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Washington University in St. Louis, 2016 
Professor Herbert Virgin, Chair 
 
 Noroviruses are a leading cause of epidemic gastroenteritis and a major health burden 
worldwide. One source for outbreaks is individuals who shed virus asymptomatically and 
persistently. Viral persistence is a successful strategy for viruses to spread, but the mechanisms 
and consequences of norovirus persistent infection are unknown. In this dissertation, we sought 
to determine the norovirus determinant(s) of persistence and explore the functions of the 
associated viral molecules. 
To determine the viral determinants of persistent infection and tropism, we used the 
murine norovirus model system in mice. Using plasmid infectious clones for persistent strain 
CR6 and non-persistent strain CW3, we mapped the viral persistence determinant to the poorly 
understood non-structural gene NS1/2. The NS1 domain of NS1/2
CR6
 was necessary and 
sufficient for persistence. A single amino acid change, NS1/2
D94E
, conferred persistence on CW3. 
Viral persistence was restricted to replication and shedding in the intestine, and NS1/2 conferred 
intestinal tropism. In contrast, the capsid protein VP1 conferred acute replication in the spleen. 
Moreover, CW3 grew more rapidly in macrophages ex vivo, and this difference mapped to VP1. 
xi 
 
Therefore, NS1/2 and VP1 are the major determinants for persistence and tropism in vivo and ex 
vivo. 
To determine a molecular function of NS1/2, we characterized its interaction with the 
host protein Vamp-Associated Protein A (VAPA). Murine norovirus replication was delayed in 
Vapa
-/-
 cells and this was rescued by exogenous VAPA. Moreover, in Vapa
-/-
 cells, NS1/2 
protein levels were decreased early during viral infection as well as with electroporated viral 
RNA. The interaction of murine norovirus NS1/2 with VAPA occurred in a region within the 
poorly conserved NS1 domain of NS1/2. Investigations in the structural basis of NS1/2-VAPA 
interaction revealed sequence and functional mimicry between the VAPA binding region of NS1 
and the host diphenylalanine-acidic-tract (FFAT)-motif that binds VAPA. The NS1/2-FFAT-
mimic interacted with VAPA similarly to bona fide host FFAT motifs. Furthermore, mutations 
within NS1/2 that disrupted interaction with VAPA inhibited viral replication. Thus, VAPA is a 
pro-norovirus host factor interacting directly with a norovirus protein that functionally mimics 
FFAT motifs to co-opt VAPA function. 
In conclusion, we mapped the norovirus determinants of persistence and tropism to 
NS1/2 and VP1. Furthermore, we determined that the NS1/2 interaction with VAPA enhanced 
murine norovirus infection. These are the first structural and functional studies to characterize 
NS1/2 in molecular detail. This work provides the basis for further exploration to identify the 
function of NS1/2 that contributes to persistent infection in mice.
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Chapter 1: 
Introduction  
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1.1 Gastrointestinal viruses and Persistence 
1.1.1 Viral models for gastrointestinal infection 
The mammalian intestinal virome is a crucial nexus of health and disease (1-7). Many 
viral families can be found in the intestine or stool of mammals, including Retroviridae, 
Herpesviridae, Coronaviridae, Parvoviridae, Adenoviridae, Astroviridae, Caliciviridae, 
Reoviridae,and Picornaviridae, Picobirnaviridae, Annelloviridae, Circoviridae, and many 
different families of bacteriophage. Several of these viruses can establish long-lasting enteric 
infection (8-15). Among these, murine norovirus (MNoV) is a powerful model virus to study 
enteric persistence. Understanding the mechanisms of persistent, enteric viral infection using the 
MNoV model system is the over-arching goal of this dissertation.  
 
1.1.2 Viral Persistence 
The establishment of a long-lasting, persistent infection is a successful strategy for 
dissemination and replication for many viruses. During persistence, viruses may continuously 
replicate (ex. Lymphocytic Choriomeningitis Virus (LCMV), Hepatitis C Virus (HCV), 
Papillomaviruses (HPV)), persist as non-replicating, latent genomes that reactivate upon 
stimulation, (ex. Herpesviruses), or may integrate into their host’s genomes (ex. Lentiviruses and 
Retroviruses). For viruses that continuously replicate, the LCMV model system has yielded 
detailed insight into host and viral mechanism of persistence. Particularly, single amino acid 
variants within two LCMV proteins, glycoprotein and polymerase, contribute to persistence (16-
20). The glycoprotein variant is associated with viral tropism in vivo (18), and variants within 
glycoprotein and polymerase that are associated with persistence permit LCMV replication in 
macrophages in vitro (16). These observations linked viral mechanisms of replication and 
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tropism with viral persistence. However, detailed mechanisms for enteric viral persistence are 
lacking. 
Viral persistence can have profound effects on their hosts. Persistent viral infection can 
lead to immune related pathologies (21), such as immunodeficiency (HIV and LCMV (22)), 
immunopathology (HCV), and autoimmunity (LCMV). Many persistent viral infections are 
associated with cancer, such as HCV, HPV, Human T-Lymphotropic Virus, Simian Virus 40, 
Epstein-Barr Virus, and Rous Sarcoma virus (23). It is unknown if persistent viral infections in 
the intestine are associated with cancer, though for bacteria persistent Helicobacter pylori 
infection leads to gastric and esophageal cancer (24). A persistent strain of MNoV is associated 
with pathology found in inflammatory bowel disease patients (2). In contrast, persistent 
infections can have beneficial effects on their hosts as well. Chronic herpesvirus infection can 
help mice resist lethal bacterial challenges (25), and reverses the effects of a specific 
immunodeficiency (26). Therefore, the mechanisms and consequences of persistent viral 
infection is an important research goal.  
 
1.2 Norovirus  
 
1.2.1 Norovirus Persistence 
Human Norovirus (HNoV) can establish persistent infections (27). Additionally, 
persistent HNoV infection is frequently asymptomatic (28-32). This may be of epidemiological 
importance because asymptomatically infected individuals may serve as reservoirs for NoV 
between outbreaks. Indeed, NoV from these individuals has been reported to initiate NoV 
outbreaks (33-36). Of additional concern are potential consequences of persistent HNoV 
infection on individuals. Multiple case reports have described severe outcomes for HNoV 
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infection (37-43). The inability for HNoV to grow robustly in small animal models has prevented 
studying the mechanisms and consequences of NoV persistence. The 1) discovery of MNoV, 2) 
the observation that not all MNoV strains establish persistent infections (15, 44), and 3) the 
engineering of genetically tractable infectious clones for MNoV (45), have collectively enabled 
the possibility to determine the mechanisms of NoV persistence.  
 
1.2.2 Norovirus Health Consequences 
HNoVs are the leading cause of non-bacterial gastroenteritis, and the primary cause of 
epidemic acute gastroenteritis (46-48). While most healthy individuals recover without 
complication, HNoVs cause significant morbidity and mortality among the young and old. 
HNoV also pose an economic burden due to lost productive work, hospitalization costs, and 
closure of hospital wards during nosocomial outbreaks. Direct healthcare costs alone are 
estimated to be $500 million annually in the US (49), and $4.2 billion worldwide ((50)). There 
are no norovirus vaccines, yet several candidates are under development (51-56). However, 
study of the basic mechanisms of replication and pathogenesis have been limited as efforts to 
robustly and reproducibly grow HNoV in small animal models or in cell culture have been 
unsuccessful.  
 
1.2.3 MNoV Pathogenesis and Immune Responses 
The discovery of Murine Norovirus (MNoV) has greatly facilitated the study of virus-
host interactions in the intestines, and specifically NoV pathogenesis and replication in vivo and 
in vitro. Major discoveries in vivo include a role for NoV in the development of the intestine (3), 
antiviral immunity in the intestine (57-59), a role for viruses in inflammatory bowel disease 
pathogenesis (2), and bacteria-virus interactions (58). However, it is an imperfect model of 
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HNoV pathogenesis. HNoV causes gastroenteritis, including vomiting and diarrhea, but there are 
no overt clinical signs in MNoV infection in WT animals. However, in Stat1
-/-
 mice, MNoV-1 
causes gastric bloating and loose stool (60). These signs of disease imperfectly model HNoV 
pathogenesis, but it should be noted that mice do not have an emetic reflex (61), so it is 
reasonable to predict MNoV evolved other mechanisms of transmission and pathogenesis.  
Viruses must in some way evade or antagonize immune responses to establish persistent 
infections (62-64). Both innate and adaptive immune responses are important for control of 
MNoV-1 in mice, which is cleared acutely in WT mice. The founding strain of MNoV, MNoV-
1, was isolated during intracranial serial passaging in mice devoid of adaptive immunity and IFN 
signaling, Rag1/Stat1
-/-
 mice (65). For adaptive immune responses, MNoV-1 can persist in  
Rag1
-/-
 mice (66, 67). Moreover, antibody production by B cells, CD4+ and CD8+ T cells are 
necessary for rapid clearance of MNoV-1 (66, 67). Furthermore, the persistent MNoV strain CR6 
induces MNoV-specific T cells, but these cells are less functional (57). Further studies are 
needed to characterize the role of adaptive immune responses against persistent MNoV strains 
such as CR6. 
Innate immune responses are important for control of MNoV. MNoV-1 is lethal in Stat1
-/-
 
and Ifnar
-/-
 mice, but is cleared acutely from immunocompetent mice (65, 68), indicating lack of 
interferon (IFN) signaling alone is sufficient for MNoV-1 lethality. IFNγ signaling is also 
important for control of MNoV-1 in mice and bone-marrow derived macrophages (BMDMs) 
(69). Furthermore, MNoV-1 replication is enhanced in mice lacking the transcription factors 
IRF1, IRF3, IRF5, and IRF7, which are involved in IFN production and signaling (68, 70, 71). 
Moreover, deletion of Ifnar
-/-
 only in macrophages or dendritic cells permits a non-lethal 
persistent MNoV-1 infection of mice (72). Host detection of MNoV-1 is mediated by the pattern 
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recognition receptor MDA-5 (73). Additionally, MNoV-1 growth in vivo is enhanced by Nlrp6
-/-
, 
a recently identified RNA-virus sensor (74). Work on the role of individual IFN-stimulated genes 
for MNoV is limited, except ISG15 has antiviral function against MNoV (75). Furthermore, 
autophagy proteins are necessary for the antiviral function of IFNγ in mice and in BMDMs (69), 
suggesting that these proteins interact with ISG(s) to restrict MNoV replication. 
Immune control of different MNoV strains is not universal. MNoV strains isolated from 
feces, such as CR6, have reduced lethality in immunocompromised mice (15, 76). Furthermore, 
IFNλ controls CR6, but not MNoV-1 subtype CW3 (59). These observations opened the 
possibility to map viral determinants for susceptibility/resistance to immune responses. A critical 
advance to accomplish this aim was the creation of DNA-plasmid infectious clones for MNoV-
1.CW3 and the CR6 (45). Single gene chimera between CW3 and CR6 revealed that the viral 
protein VP1 determines MNoV lethality in immunocompromised mice (77, 78) and is a partial 
determinant for sensitivity to IFNλ in mice (59). This viral genetic system will permit further 
mapping of the viral genetic determinants of traits that differ between CW3 and CR6. 
 
1.2.4 Norovirus Tropism 
A substantial limitation for NoV studies is the lack of definitive evidence for the cell 
types in which NoV replicates in vivo in immunocompetent and tractable model organisms. 
Exhaustive efforts have been made to this end (reviewed in (79)). Evidence to date does not 
support a role of replication in epithelial cells, but rather in macrophages (80-82), dendritic cells 
(80, 83), and B cells (84, 85). Detailed studies of mechanisms of NoV pathogenesis, immune 
responses, mechanisms of persistence, and many other studies will require this breakthrough. 
 Host factors determine an individual's susceptibility to infection by NoV. In a strain 
dependent fashion, HNoV requires carbohydrates, specifically histo-blood group antigens 
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(HGBAs), at the cell surface to enable virus attachment (86-93). This has profound consequences 
for HNoV host range. Individuals who lack the protein FUT2, an enzyme necessary for 
production of HGBAs, are not susceptible to challenge infections by HNoV (87). MNoV also 
binds carbohydrates at the cell surface (94, 95). Mutations in VP1 that attenuate the ability for 
MNoV to bind carbohydrates exhibit altered tropism in mice (95).  
 
1.2.5 Norovirus Molecular Virology 
NoV is genus within the Caliciviridae family. The NoV genus is further organized into 
seven phylogenetically classified “genogroups” based on VP1 sequence (96, 97). NoVs are 
small, non-enveloped viruses encoded by a single-stranded positive-sense RNA genome. The 5’ 
terminus of vRNA is covalently linked to a small viral protein (VPg). The genome is organized 
into three Open Reading Frames (ORFs), and a fourth ORF unique to MNoV (Figure 1.1A). 
ORF1 contains the Non-Structural (NS) proteins NS1/2 through NS7. ORFs 2 and 3 encode the 
structural proteins VP1 and VP2, which make up the viral capsid (98). ORF4 overlaps with 
ORF2 and encodes an immune-evasion molecule, VF1, which is unique to MNoV (99).  
On a cellular level, some details of the NoV life cycle are known (Figure 1.1B). Both 
MNoV and HNoV bind to carbohydrates at the cell surface (94, 100). Recently, a proteinaceous 
receptor for MNoV was discovered, CD300lf (in press). MNoV is taken up through an endocytic 
process mediated by dynamin, cholesterol (101, 102), and possibly ceramide (103), and releases 
viral genome into the cytoplasm. ORF1 polyprotein is translated from the virion RNA. This is 
mediated by interactions of VPg with eIF4G (104, 105) and eIF4E (106) and results in NoV 
regulating host translation (107). The ORF1 polyprotein is proteolytically processed into non-
structural proteins by the virally encoded protease (NS6) (108). Non-structural proteins then 
collaborate to re-organize host membranes to form a membranous structure on which viral 
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replication occurs, i.e. the replication complex (RC) (80, 109). It is undefined what functions of 
NoV and host proteins, lipids, and pathways are required for formation of RCs. Nevertheless, 
precedents from other viruses are discussed below. However, all MNoV non-structural proteins 
localize with RCs during infection (109), and when transiently transfected, NSs localize with 
different markers of membranous sub-cellular structures (110). Virally encoded RNA-Dependent 
RNA Polymerase (NS7) synthesizes negative-strand RNA. This negative strand then serves as 
template for amplification of genomic viral RNA (vRNA) as well as the sub-genomic RNA. 
ORFs 2-4 are translated from sub-genomic RNAs. vRNA and capsid proteins VP1 and VP2 
assemble into virions that are released from cells. 
As a single-stranded RNA virus, the NoV genome is folded into higher order secondary 
and tertiary structures (111-114). These structures have been observed at the 5' and 3' termini of 
the genome, thus overlapping the coding sequence for NS1/2 and NS7 respectively. Another 
structured region immediately precedes the sub-genomic RNA within NS7 gene, called the sub-
genomic promoter (112). These structures are critical for viral replication. These RNA structures 
overlap coding sequence for NS1/2, NS7, and VP2, thus placing additional constraints on the 
ability for these proteins to evolve.  
 
1.3 Norovirus Non-Structural Protein NS1/2 
NS1/2 is the first NoV protein translated upon infection of a cell. It is rapidly cleaved at 
its C-terminus by the viral protease NS6, separating NS1/2 from NS3 (108). Therefore, NS1/2 
likely functions independently of its temporary conjugation to NS3 in the MNoV polyprotein.  
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1.3.1 NS1/2 Domains 
Three domains comprise NS1/2, the NS1, NS2, and predicted trans-membrane domains 
(115-117). Nearly nothing is known about the NS1 domain.However, the MNoV NS1 domain in 
isolation has a structured fold preceded by an unstructured region (117, 118). The NS2 domain is 
well conserved among the NoV genus. Importantly, the NS2 domain contains a predicted protein 
fold, termed NlpC/P60, seen in all kingdoms of life (119). Proteins with this fold have enzymatic 
activities, including phospholipases, proteases, and acyltransferases, suggesting that NS1/2 may 
be an enzyme. NS2 specifically resides in a clade whose prototypical member is mammalian-
encoded Lecithin Retinol Acyltransferase (LRAT). LRAT and LRAT-like Hrev107 modify 
lipids, and Hrev107 modulates cellular proliferation (120, 121). Two genera within 
Picornaviridae also encode LRAT-like molecules, which include the viruses Aichi Virus (AiV), 
Avian encephalomyelitis Virus (AeV), Human Parechovirus (HPaV), and Ljungan virus (LjV) 
(119, 122, 123), which will be discussed below. Finally, a predicted trans-membrane region 
(TM) occupies the C-terminal portion of NS2 domain.  
Some evidence evokes the idea that NS1 and NS2 may act independently of each other. 
Two caspase-3 cleavage site separate MNoV NS1 and NS2 (108), and cleavage products are 
visible by 12 hours post-infection (HPI) (108, 117). In collaboration with cellular factors, NS6 
may cleave a site near the HNoV NS1/NS2 predicted junction (124). These observations support 
the possibility that NS1 and NS2 can function both together and separately during the virus life 
cycle. Functional significance of NS1/2 cleavage is lacking. 
 
1.3.2 NS1/2 Subcellular Localization 
NS1/2 associates with membranes and the viral RC. The RC is a membranous structure 
organized by many RNA-viruses that permits efficient virus replication (reviewed in (125-128). 
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RCs also serve immune evasive function in two ways: 1) by secluding viral molecular patterns 
such as dsRNA sensed by host proteins that activate antiviral responses, and by 2) disrupting 
host membranes necessary for expression and secretion of antiviral molecules (129). Two 
separate strains of HNoV NS1/2 associate with Golgi markers as seen by microscopy and sub-
cellular fractionation (115, 116). These strains also disrupt the Golgi apparatus morphology 
(115). NS1/2 acts as an integral membrane protein, though this was not dependent on its 
predicted TM (116), possibly by binding strongly to the integral membrane protein VAMP 
(Vesicle-Associated Membrane Protein)-Associated Protein (VAPA). It is neither known if 
MNoV binds VAPA nor if this interaction is important for replication. For MNoV NS1/2, 
overexpressed NS1/2 localizes with ER markers, but not Golgi markers (110). Moreover, during 
infection NS1/2 overlaps entirely with double-stranded RNA, which forms during viral RNA 
synthesis and is a definitive feature of RCs. NS1/2 also forms puncta outside RCs (109). It is 
unknown what cellular markers these puncta localize with or what functions they serve. 
 
1.3.3 NS1/2 Protein Interactions 
A number of host and viral proteins have been reported to interact with NS1/2. As 
discussed above, VAPA interacts with NS1/2. NS1/2 also interacts with the viral protein NS4 
(130), but the contributions of this interaction to viral replication have not been investigated. 
Lastly, HSP90, a host chaperone that stabilizes and assists proper protein folding, also binds 
NS1/2 (131). NS1/2 is produced in lower levels upon pharmacological inhibition of HSP90 
(131), while this was not true for all viral proteins. This is intriguing as the NS proteins cleaved 
from the polyprotein are produced in relatively equimolar ratios in WT cells. This argues NS1/2 
production is uniquely influenced by the function of HSP90. However, while HSP90 was 
demonstrated to be beneficial for MNoV growth, it cannot be imputed this is primarily due to 
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HSP90-NS1/2 interaction as HSP90 also binds and stabilizes VP1 and the 5' end of MNoV 
genomes (131). Identification of additional NS1/2 client proteins, and uncovering their roles in 
MNoV infection, will be critical to understanding the role of NS1/2 during MNoV infection.  
The interaction of NS1/2 with HSP90 represents an example of how proteostasis, the 
regulation of protein production and degradation within the cell, can influence NoV infection. 
Further evidence for the importance of proteostasis during MNoV infection comes from studies 
on the unfolded protein response (UPR). The UPR is a key regulator of proteostasis. Activation 
of the UPR is detrimental to MNoV replication (132). How NS1/2 production is regulated during 
infection, and if the UPR plays a role, will be resolved with further experimentation. 
 
1.3.4 NS1/2 Functions 
Many observations support that NS1/2 is involved in basic virus replication. First, NS1/2 
co-localizes with the viral RC (109). Second, mutagenizing the NlpC/p60 predicted catalytic 
residue in NS1/2, MNoV-NS1/2
C216A
, prevents recovery of plasmid-derived virus (unpublished 
data). Third, Thorne et al. created a library of MNoV clones whose genomes were saturated with 
small insertions (130). Among viruses with insertions in NS1/2, viruses were recovered in cell 
culture only with insertions in three discrete regions, all confined to the NS1 domain. This 
suggests the NS2 domain has critical function(s) for virus replication, as disruption of NS2 with 
small insertions did not produce virus. Fourth, NS1/2 enhances RNA synthesis activity of NS7 in 
a cell-based functional assay (133). Fifth, virus-encoded homologues of NS2 contribute to virus 
replication, discussed next.  
The functions of homologues for the NS2-domain suggest NS1/2 has a fundamental role 
in viral replication. For example, the AiV homologue for NS1/2, the 2A protein, is required for 
viral replication as mutating the predicted catalytic sites within the NlpC/P60 fold inhibits 
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synthesis of viral RNA both in cells and in a cell-free system (134). The initial round of 
translation is unaffected in these systems, strongly supporting that the defect is at a step 
downstream of protein synthesis. In support of a function at RNA replication, AiV 2A binds to 
AiV 3CD protein shown by M2H (135) which has a role in replication of viral RNA. 
Furthermore, 2A in HPaV binds specifically to the 3’UTR of the genome, consistent with a role 
for RNA synthesis (136). Finally, HPaV 2A associates with viral RC (137), though notably 
extra-RC 2A diffuses throughout the entire cellular space, in contrast to cytoplasmic puncta 
formed by NoV NS1/2. The mechanisms through which these homologues function may help 
predict NS1/2 function in MNoV lifecycle. 
In line with the finding that over-expressed NS1/2 associates with ER and Golgi 
membranes, two additional observations support that NS1/2 disrupts secretion. First, over-
expressing NS1/2 disrupts the Golgi apparatus (115). Second, over-expressed VSV-G normally 
accumulates on the plasma membrane. Simultaneous over-expression of NS1/2 and VSV-G 
prevents cell surface expression of VSV-G (116). These results suggest NS1/2 participates in 
membrane re-modeling during viral replication or perhaps immune evasion.  
 
1.4 VAPA 
VAPA is a type II endoplasmic reticulum (ER) resident protein that is conserved in 
eukaryotes (138). VAPA is comprised of a Major Sperm Protein (MSP) domain, a Coiled-Coil 
domain (CCD), and a transmembrane domain. Initially found to bind SNAREs (139-141), VAPA 
also binds a variety of client interacting proteins (138). Importantly, through the cytosolic MSP 
domain, VAPA interacts with client proteins. These proteins interact with VAPA-MSP via a 
diphenylalanine acidic tract (FFAT) linear motif (142-146). VAPA client proteins have roles in 
diverse cellular processes, including proteostasis (147-154), non-vesicular lipid transfer (138, 
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145, 155-160), membrane morphology (154, 161, 162), and membrane contacts (154, 157, 159, 
163-165), 
VAPA performs important functions during infection as both microbes and antimicrobial 
host molecules target VAPA and its client proteins. VAPA and its paralog VAPB enhance the 
replication of Hepatitis C virus (166, 167), rhinoviruses (168), tombusvirus (169, 170), and the 
intracellular bacteria Chlamydia trachomatis (171, 172). Some of these microbes encode 
molecules that interact with VAPA, VAPB, and/or its client proteins, including HCV proteins 
NS5a and NS5b (166, 167), tombusvirus p33 (169, 170), and C. trachomatis IncD (171, 172). 
VAPA and VAPA client proteins may assist in organization of membranous structures critical 
for virus replication (173, 174), possibly by manipulating the lipid composition of these 
membranes (168-170). Furthermore, VAPA binds to the interferon stimulated genes IFITM3 
(175) and RSAD2 (176, 177), suggesting that VAPA may be involved in antiviral responses.  
Regulation of VAPA function by competition between VAPA-client proteins has been 
observed in several settings. First, VAPA interacts competitively with FFAT motifs and either 
FAF1 or ATF6 that may mediate switching between regulating lipid trafficking and ER quality 
control (150). Second, IFITM3 competitively binds VAPA away from lipid transfer proteins 
(LTPs); this correlates with cholesterol accumulation in endosomes and impaired entry of VSV 
and influenza into cells (175). It is unknown if IFITM family members are antagonistic to NoV 
replication. A separate IFN stimulated VAPA-client protein, RSAD2, antagonizes HCV infection 
by disrupting VAPA-NS5a interaction (176, 177). Together these observations raise the question 
how frequently VAPA is regulated by competition in physiological processes or during microbial 
infection. 
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In addition to those discussed above, non-vesicular, protein-mediated lipid transfer is the 
primary function of VAPA and the most studied function in relation to microbial infection. 
Examples from positive-sense RNA viruses demonstrate possible functions in NoV. 
Picornaviruses, Hepatitis C Virus (HCV), and tombusviruses require VAP proteins (166, 168, 
169, 173, 178-180) and the VAP-client protein OSBP (168, 169, 181). Domain mapping of 
OSBP revealed OSBP-VAP interaction is required to enhance HCV replication. Cholesterol is 
enriched at RCs for HCV and picornaviruses (182-187), and OSBP is thought to be a major 
mechanism for this enrichment (168, 186-188). Proper recruitment and activity of OSBP requires 
the accumulation of PI4P at picornaviruses and HCV replication complexes (187-190). PI4P 
lipid-modification recruits OSBP via a PH-PI4P binding domain. This recruitment is required for 
HCV replication, as reconstitution of OSBP depleted cells with OSBP lacking the PH domain 
does not rescue viral replication (188). The specific role of cholesterol in HCV infection is 
unclear, but cholesterol enrichment does induce biophysical changes to membranes, such as 
causing negative curvature and reduced membrane fluidity. These characteristics may be 
necessary for proper replication complex assembly and function. It is unknown if cholesterol or 
PI4P are enriched at NoV replication complexes, or if disruption of lipid trafficking perturbs 
viral replication. However, in a STAT1- and IRF1-dependent fashion, IFNγ inhibits cholesterol 
and lipid metabolism (70), suggesting the possibility that lipid metabolism is a pro-viral host 
process.  
VAP proteins make membrane contact sites (MCS) which are associated with the viral 
replication of tombusviruses, a genus of plant viruses. Tombusviruses require VAP protein 
homologues to replicate efficiently (169). OSPB Related Proteins (ORPs) are required to enrich 
tombusvirus RCs with cholesterol (169, 170). Critically, MCSs can be detected in close 
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proximity to tombusvirus replication complexes (169). Thus, tombusviruses may thus take 
advantage of MCSs to channel the appropriate lipids to replication complexes. 
Lastly, the intracellular bacteria Chlamydia trachomatis also requires VAP proteins, and 
encodes a virulence factor IncD that interacts with the VAP-client protein CERT (171, 172). 
VAP and CERT localize with IncD at ER-bacterial inclusion MCSs. At these sites, CERT 
transfers ceramide to the bacterial inclusion that is processed to sphingomyelin and used by the 
bacterium. There are no precedents for viruses requiring CERT. While there is some evidence for 
a role for ceramide in NoV entry into cells (103), it is unknown if CERT, ceramide, or 
sphingomyelin are required for viral replication. 
 
1.5 Rationale 
NoV is an important human pathogen, yet there is limited understanding of viral and host 
molecules that regulate replication in vivo and in cell culture. Furthermore, there are additionally 
few tractable model systems to study virus-host interactions during enteric viral persistence. 
Virus persistence within individuals is an important mechanism for maintaining reservoirs to 
infect others, but also has consequences for the host. Furthermore, the study of persistent extra-
intestinal viral infection has resulted in many important immunological and virological 
observations, but it is unclear if these observations are relevant to enteric virus infection. 
Therefore, understanding the mechanisms and consequences of enteric viral persistence is an 
important goal.  
We aimed to determine the MNoV molecular determinants of persistence and tropism in 
the intestine, then to characterize the function of these molecules. We found NS1/2 is the major 
determinant of tropism and persistence, and further described in detail the molecular interaction 
between NS1/2 and the host protein VAPA.  
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1.6 Contribution to Field 
 In this dissertation, we describe the mapping of MNoV genetic determinants for 
persistent replication and tropism in the intestine. These studies advanced our understanding of 
how viruses and hosts interact in the intestinal tract and provide a starting point to understanding 
the viral mechanisms of persistent infection. This work is also the first detailed structure-function 
description of the NoV protein NS1/2. We also identified the first microbial mimic of the FFAT 
host protein motif.  
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1.8 Figures 
 
 
Figure 1.1. Organization of NoV genome and viral life cycle. 
(A) Organization of NoV genome adapted from (14). Offset rectangles represent different Open 
Reading Frames (ORFs). Bolded line beneath represents subgenomic RNA, transcribed from 
minus strand beginning at a subgenomic promoter within NS7 coding sequence. 
(B) Life cycle of NoV. Attachment is facilitated by binding carbohydrate and proteinacous 
receptors, followed by endocytosis. Viral genomes are released from capsid into cytoplasm 
where ORF1 is translated. Viral NS proteins remodel membranes to form RCs. At RCs, vRNA is 
copied into minus-strand, from which more vRNA is synthesized as well as sub-genomic RNAs. 
ORFs 2-4 are translated from sub-genomic RNAs, producing capsid proteins VP1 and VP2, as 
well as VF1. vRNAs are encapsidated, and virus is released through undefined mechanisms.  
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determinants of tropism and persistence in 
mice  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In addition to unpublished data, this chapter is adapted from:  
Nice TJ, Strong DW, McCune BT, Pohl CS, Virgin HW. 2013. A Single-Amino-Acid Change in 
Murine Norovirus NS1/2 Is Sufficient for Colonic Tropism and Persistence. J Virol 87:327–34. 
DOI: 10.1128/JVI.01864-12.  
Copyright © American Society for Microbiology 
38 
 
2.1 Abstract 
Noroviruses (NoVs) are a leading cause of epidemic gastroenteritis and a major health 
burden worldwide. One source for outbreaks is individuals persistently shedding virus 
asymptomatically. Viral persistence is a successful strategy for viruses to spread, but the 
mechanisms and consequences of NoV persistent infection in vivo are unknown. To determine 
the viral determinants of persistent infection and tropism, we used the murine norovirus (MNoV) 
model system. MNoV strains are phenotypically dimorphic for persistence; strain CR6 is 
persistent but CW3 is not persistent. Using plasmid infectious clones, we mapped the viral 
persistence determinant to the poorly understood non-structural gene NS1/2. Further, the NS1 
domain of NS1/2
CR6 
was necessary and sufficient for persistence. Mutations within the NS1 
domain prevented CR6 from establishing persistent infection. Strikingly, a single amino acid 
change, NS1/2
D94E
, conferred persistence on CW3. NS1/2 mutants had a delay in viral release 
from cells in culture. Additionally, we observed persistence is restricted to replication and 
shedding in the intestine, and NS1/2 confers intestinal tropism. In contrast, the capsid protein 
VP1 conferred acute replication in the spleen. Finally, we observed CW3, but not CR6, grew 
rapidly in macrophages differentiated from bone marrow. This difference mapped to VP1. 
Therefore, persistence and intestinal tropism are conferred by NS1/2, and splenic tropism and the 
ability to grow in macrophages ex vivo is conferred by VP1. In conclusion, we mapped MNoV 
persistence and tropism determinants to NS1/2 and VP1. These studies highlight the strength of 
phenotype mapping using MNoV infectious clones. 
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2.2 Introduction 
HNoVs are a leading cause of non-bacterial gastroenteritis, and the primary cause of 
epidemic gastroenteritis (reviewed in (1)). While most healthy individuals recover without 
complication, HNoVs cause significant morbidity and mortality among the young and old (2-8). 
HNoV also pose an economic burden due to lost productive work and closure of hospital wards 
during nosocomial outbreaks. Hospitalization costs alone are estimated to be $500 million 
annually in the US (9).  
Multiple observations, from experimental infections to longitudinal epidemiological 
studies, support that HNoV can establish prolonged infections up to weeks and months (10-15). 
Additionally, persistent HNoV infection is frequently asymptomatic (11, 13, 15-17). This may be 
of epidemiological importance because asymptomatically infected individuals may serve as 
reservoirs for NoV in between outbreaks. Indeed, these individuals have been reported to initiate 
NoV outbreaks (13, 18-20).  
NoV is a genus of non-enveloped, positive-sense RNA viruses within the Caliciviridae 
family. NoVs are grouped into seven clades, genogroups GI-GVII. GI, GII, and GIV cause 
human disease, and GV encompasses more recently discovered rodent NoVs, including MNoV 
(21). The NoV genome encodes nine known proteins: seven non-structural (NS) proteins derived 
by proteolysis of the ORF 1 polyprotein (22) and two structural proteins, VP1 and VP2 derived 
from ORFs 2 and 3 respectively (23). MNoV additionally encodes the virulence protein VF1 
from ORF 4 (24). The host requirements for NoV replication as well as NoV pathogenesis has 
historically been limited by the lack of replication of HNoV in cell culture or in small animal 
models. Only recently has limited HNoV replication been achieved in mice or cell lines (25, 26). 
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As MNoV robustly replicates in mice and cells, it serves as a powerful system for functional 
molecular studies of NoV (23, 27). 
The discovery of MNoV has greatly facilitated the study of NoV pathogenesis and 
replication in vivo and in vitro. The founding strain of MNoV, MNoV-1, was found during 
intracranial serial passaging in Rag1/Stat1
-/-
 mice (28). It is lethal in Stat1
-/-
 and Ifnar
-/-
 mice, but 
is cleared acutely from immunocompetent mice (28, 29). However, MNoV strains subsequently 
isolated from feces are not lethal in immunocompromised mice (30). Furthermore, MNoV-1 does 
not establish persistent infection in mice, but fecal isolates predominately do persistently infect 
mice (30, 31). The creation of DNA-plasmid infectious clones (32) for MNoV1.CW3 and the 
MNoV fecal isolate CR6 aided the discovery that the viral protein VP1 determines MNoV 
lethality in immunocompromised mice (33, 34). However, the precise function(s) of VP1 
connected to MNoV lethality has not been elucidated, nor are the MNoV genetic determinants 
for viral persistence known.  
The N-terminal protein product in the polyprotein, NS1/2, is comprised of three domains: 
NS1, NS2, and a putative transmembrane (TM) domain (35). In MNoV, NS1 domain in isolation 
has a structured region preceded by an intrinsically disordered domain (35, 36). NS2 encodes a 
domain that might have enzymatic function (38). Ectopically expressed NS1/2 from GI HNoV 
(NS1/2
GI
) disrupts the Golgi apparatus and vesicular trafficking (39, 40) and is reported to 
interact with the host protein Vamp-Associated-Protein A (VAPA) (39). The role of VAPA 
interactions with NS1/2 during viral replication has not been defined.  
We sought to identify the viral determinants of persistent infection in mice. We found the 
viral gene NS1/2 from persistent MNoV strain CR6 could confer persistence on non-persistent 
strain CW3. Furthermore, the NS1
CR6
 domain of NS1/2 was necessary and sufficient for viral 
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persistence. Strikingly, a single amino change within CW3 NS1 domain, D94E, conferred 
persistence on CW3. The site of persistence was the gastrointestinal tract, and D94E conferred 
colonic replication on CW3. All viruses grew equivalently in the RAW264.7 cell line, but pCR6-
NS1
CW3
 had a delay in viral release from cells. Lastly, the viral capsid protein VP1
CW3
 was 
associated with replication in the spleen and in primary macrophages ex vivo. These data extend 
a primary role for NS1/2 in viral persistence and roles for both NS1/2 and VP1 in viral tropism. 
  
42 
 
2.3 Results 
 
2.3.1 MNoV strain CR6, but not CW3, is persistently shed in mice stool.  
MNoV strain CR6 establishes persistent infection but CW3 does not. Using cDNA of 
CR6 and CW3 cloned into DNA plasmid infectious clones, we produced virus to verify plasmid-
derived virus establishes persistence similar to original virus isolates. pCR6 was robustly 
detected in mouse stool by seven days post infection and maintained high levels of shedding as 
late as 70 days post infection (Figure 2.1A). pCW3 was marginally shed in stool three days post-
infection, and was undetectable in stool by 14 days post infection (Figure 2.1A). 
To determine what genetic elements of MNoV contribute to persistence, we generated 
single gene chimera between pCR6 and pCW3 (Figure 2.1B). pCW3-NS6
CR6
 did not produce 
virus, so we could not test this chimera for persistence (data not shown).  pCW3-NS1/2
CR6
 
chimera persistently shed from mice, and no other pCW3 chimera gained the ability to persist 
(Figure 2.1D-E). The reciprocal virus, pCR6-NS1/2
CW3
, did not produce virus, so we could not 
test this mutant for the necessity of NS1/2 to establish persistence. Notably, VP1, which forms 
the proteinaceous exterior capsid of MNoV virions, was unrelated to persistence; pCW3-VP1
CR6
 
did not persist, and pCR6-VP1
CW3
 established a persistent infection (Figure 2.1F). We concluded 
NS1/2
CR6
 is sufficient to confer persistence on pCW3.  
 
2.3.2 NS1 domain is necessary and sufficient for MNoV persistence in mice.  
To identify which domains contributed to persistent infection, we engineered CR6 and 
CW3 NS1/2 domain chimera. NS1/2 is divided into two domains, NS1 and NS2, determined by 
level of conservation. NS1 is poorly conserved among NoV genogroups, but NS2 is well 
conserved (Figure 3.8A herein). Additionally, the domains are cleaved into individual molecules 
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during infection, most likely at two caspase 3 cleavage sites dividing the domains (22). NS1 was 
sufficient to confer persistence on pCW3, but pCW3-NS2
CR6
 did not persist (Figure 2.1F). 
Furthermore, pCR6-NS1
CW3
 did not persist (Figure 2.1F). pCR6-NS2
CW3
 inconsistently produced 
virus from infectious clones, but in one experiment that did recover virus, it established 
persistent infection (data not shown). Therefore, the NS1
CR6
 domain is necessary and sufficient 
for persistence. 
 
2.3.3 Single and combination NS1 residues are necessary and sufficient for 
persistence 
The NS1 domains from CR6 and CW3 differ by 10 residues across 121 residues (Figure 
2.2B). To map in detail which residues within NS1 contributed to persistence, we aligned the 
NS1 domain from persistent strains of MNoV with the non-persistent CW3. Only one residue 
was in common with persistent strains, E94, that differed from the CW3 residue D94 (Figure 
2.2A). We introduced D94E into pCW3 and E94D into pCR6 to test the role of residue 94 in 
persistence. pCW3-NS1
D94E
 established persistent infection in mice (Figure 2.2C). However, 
pCR6-NS1
E94D
 established persistent infection, suggesting other residues contribute to persistent 
infection in CR6 (Figure 2.2C). To test if these other residues outside NS1 contributed to 
persistence in CR6, we restored D94E in non-persistent pCR6-NS1
CW3
. pCR6-NS1
CW3-D94E
 
established persistent infection (Figure 2.2C).  
 
2.3.4 Persistent and non-persistent viruses grow equivalently in cell culture, 
but pCR6-NS1 mutants are delayed in release from cells 
To test if CW3, CR6, CW3-NS1
D94E
, or CR6-NS1
CW3
 mutant strains replicated 
differently in cell lines, we infected RAW 264.7 macrophage-like cells. All viruses replicated 
equivalently in a single replication cycle or multiple replication cycles of growth (MOI 5 or 0.05 
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respectively) (Figure 2.3A). To test if all viruses are similarly released from cells, we separated 
cells and media at 12 hours post infection, when a complete life cycle of MNoV is completed 
(41). pCR6, pCW3, and pCW3-NS1
D94E
 had equivalent levels of virus in cells as supernatant, but 
CR6-NS1
CW3
 had lower levels of supernatant virus (Figure 2.3B). However, by 24 hours, all 
virus strains had equivalent levels of virus in cells or supernatant (Figure 2.3B). Therefore, the 
ability to persist in mice did not correlate with a virus growth advantage in a cell line. 
Nevertheless, a mutant NS1/2 had impaired viral release from cells. 
 
2.3.5 VP1 and NS1/2 are determinants of tissue tropism 
As pCR6 is persistently shed in stool, we reasoned the site of persistent replication is the 
GI tract. To determine which portion of GI tract supports persistent infection, we isolated tissues 
from stomach, duodenum, jejunum, ileum, cecum, proximal colon, and distal colon. We found 
increasing levels of MNoV genomes further down the GI tract, reaching peak levels at the 
proximal colon, but with low levels in the distal colon (Figure 2.4A). To assess if other tissues in 
mice support persistent infection, we isolated proximal colon, spleen, and mesenteric lymph 
nodes (MLN) infected with pCW3 or pCR6. We detected pCR6 genomes in the proximal colon 
and MLN from one to fourteen days post infection, but we never detected pCR6 in the spleen 
(Figure 2.4B). We also detected pCW3 in MLN and spleen from day three to seven, but not in 
the proximal colon (Figure 2.4B). However, we did not detect pCW3 genomes in any tissue by 
14 days post infection (Figure 2.4B). To test if VP1 contributed to tissue tropism, we tested to 
which tissues pCR6-VP1
CW3
 and pCW3-VP1
CR6
 localized. We detected equivalent levels of 
pCR6-VP1
CW3
 and pCR6 in MLN and proximal colon seven days post infection. We also 
detected pCR6-VP1
CW3
 in the spleen at day 3, but not day 35 (Figure 2.4C, E). Moreover, similar 
to pCR6, pCR6-VP1
CW3
 replicated in the proximal colon and MLN both acutely and persistently 
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(Figure 2.4C, E). Like pCW3, we did not detect pCW3-VP1
CR6
 in the proximal colon. We 
additionally did not detect pCW3-VP1
CR6
 genomes in the spleen and reduced levels in the MLN 
(Figure 2.4C). Because VP1 did not govern colonic replication, and pCW3-NS1/2
D94E
 was 
persistently shed in stool, we wondered if NS1/2 contributed to replication in the proximal colon. 
We detected pCW3-NS1/2
CR6
 and pCW3-NS1/2
D94E
 genomes in the proximal colon, as well as 
the spleen and MLN (Figure 2.4D). Furthermore, we did not detect pCR6-NS1
CW3
 genomes in 
colon, spleen, or MLN. In contrast, pCR6-NS1
CW3-D94E
 was robustly detected in the colon 
(Figure 2.4D). These results indicate the site of MNoV persistence is the GI tract. Moreover, 
NS1/2 and VP1 influenced tissue tropism for MNoV. VP1 dictated spread to the spleen, and 
NS1/2 was necessary and sufficient for colonic tropism for pCW3 and pCR6, respectively.  
 
2.3.6 VP1 is the determinant for MNoV growth in BMDMs 
The previous results mapped on a tissue level the tropism for pCW3 and pCR6. To 
determine the cellular tropism of pCW3 and pCR6, we tested viral growth in primary cells ex 
vivo. pCW3 grew robustly but pCR6 replicated slower in macrophages differentiated from bone 
marrow (i.e. bone marrow-derived macrophages (BMDMs)) (Figure 2.5A). To test if the barrier 
to infection for pCR6 was at viral entry, we bypassed viral entry by electroporating viral RNA 
from pCR6 and pCW3 into BMDMs. pCR6 and pCW3 replicated equivalently in BMDMs at 12 
hours post infection, though pCR6 had diminished levels of virus at 48 hours post infection 
(Figure 2.5B). To identify what viral factors contributed to replication in BMDMs, we tested 
single gene chimera of pCW3 or pCR6. The ability to grow in BMDMs mapped to the capsid 
protein, VP1 (Figure 2.5C). VP1 is comprised of a shell (S) and protruding (P) domain. The 
protruding domain extrudes from the virion, and likely contacts putative receptors. The pCR6 
expressing P
CW3
 gained the ability to grow in BMDMs (Figure 2.5C). Furthermore, pCR6-
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VP1
CW3
 and pCR6-P
CW3
 replicated equivalently to CW3 at all time points, and pCW3-VP1
CR6
 
replicated equivalently to pCR6 (Figure 2.5D). Therefore, VP1 is the viral determinant for 
growth in ex vivo cell type BMDMs. 
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2.4 Discussion 
We found that the poorly studied MNoV gene NS1/2 governs enteric viral persistence. 
Furthermore, the NS1 domain within NS1/2 was necessary and sufficient for persistence, and a 
single coding change, NS1
D94E
, was sufficient for pCW3 to establish persistent infection. NS1/2 
also governs colonic tropism, the site of persistent infection, whereas VP1 determined splenic 
tropism and growth in BMDMs.  
 
2.4.1 MNoV: a model system of enteric viral persistence. 
HNoV can be shed for prolonged periods of time, which can initiate new outbreaks, thus 
maintaining HNoV in the population. Furthermore, astroviruses, adenoviruses, enteroviruses, and 
rotaviruses can all persistently infect humans (42-44). Nevertheless, MNoV is the first small 
animal model of viral persistence. Using this system, we identified the first genetic model of 
persistence. Studies using the MNoV persistence model system described herein since its 
original publication show the promise of MNoV to learn about viral-host interactions during 
persistence in the intestines (45-49). 
 
2.4.2 NoV Tropism and Persistence 
NoV persistence was associated with colonic tropism as has been reported (50, 51). Why 
persistence is restricted to the intestine in immunocompetent animals is unclear. A variety of 
mechanisms contribute to viral persistence in other models, but all viruses must escape 
elimination by immune responses. This is accomplished by antagonism, evasion, or antigenically 
shifting from innate and adaptive immune responses (52-54). For the MNoV-1 strain, adaptive 
and innate responses are both necessary to clear acute infection (29, 48, 55, 56). Furthermore, 
suboptimal intestinal innate and adaptive immune responses are associated with CR6 persistence 
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(47, 57, 58). These observations argue that CR6 antagonizes or evades a productive immune 
response. The gastrointestinal tract is a unique immunological site due to the vast abundance of 
the microbial flora. The microbial flora predisposes the intestine to immune regulation that CR6 
may coopt to establish persistence (58).  
 
2.4.3 NS1/2 and Persistence and Tropism 
pCW3-NS1
D94E
 and pCR6-VP1
CW3
 both establish persistent infection, leading us to 
conclude that NS1/2 is the major viral determinant of persistence. However, additional 
experimentation revealed NS1/2 is sufficient only at a low viral dose (3 x 10
4 
PFU). pCW3-
NS1
D94E
 sporadically establishes persistence at higher doses (1x10
6
 PFU), but the double mutant 
pCW3-NS1
D94E
-VP1
CR6
 invariably establishes persistence at high dose (57). Furthermore, 
VP1
CW3
 is a determinant for IFNλ induction in mice (57). pCW3-NS1D94E at high dose persists in 
Ifnlr-/-, arguing VP1
CW3
-linked induction of IFNλ controls replication of pCW3-NS1D94E. 
Nevertheless, pCW3 does not persist in Ifnlr-/- (57). This implies that VP1 and NS1/2 work in 
concert to avoid induction of IFNλ and replicate in the intestine, respectively, to establish 
persistence. Could persistent NS1/2 antagonize IFNλ? It remains unclear if NS1/2 function 
intersects IFNλ signaling. Nevertheless, the observation that persistently replicating pCR6 is 
cleared by IFNλ treatment indicates pCR6 is susceptible to IFNλ signaling, if IFNλ is produced 
sufficiently (57). However, pCR6-VP1
CW3
 persists and induces IFNλ (57). Therefore, evasion of 
IFNλ expression is not the sole correlate of MNoV persistence. In conclusion, unless it is true 
that NS1/2
CR6
 antagonizes IFNλ function, another viral gene within CR6 contributes to 
persistence by evading IFNλ. Should NS1/2CR6 antagonize IFNλ, why isn’t pCW3-NS1D94E 
sufficient to persist at high dose? Perhaps NS1
D94E
 does not have the full potency of activity as 
NS1
CR6
. Experiments elucidating the specific cells inducing and responding to IFNλ, the 
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mechanism of VP1
CW3
 induction of IFNλ, IFNλ ISGs that are antiviral against MNoV, the 
function of the NS1 domain, and MNoV tropism will be needed to fully answer these questions. 
 Clues for how NS1/2 functions in persistence may be found from studies in cell lines. 
NS1/2 is associated with replication complexes (59, 60) and disrupts intracellular membrane 
trafficking (39). Furthermore, the NS1 domains from persistent variants of NS1/2, CR6 and 
D94E, differ structurally from non-persistent CW3 (36). Lastly, the NS2 domain contains a 
predicted permutated NlpC/p60 fold that among closely related sequences modifies lipids (38, 
61-64). Therefore, it is possible that in vivo persistence is linked to the function of NS1/2 in 
infected cells to modify lipids or membranes. We did observe a delay of viral release from cells 
for pCR6-NS1
CW3
, though it was unclear how this virus grew equivalently in a multi-step growth 
curve. How MNoV virions are released from cells is poorly understood, so the viral and host 
factors that contribute to viral egress are unknown. The observation that NS1/2 mutants impair 
accumulation of virus in media is the first example of a NoV protein involved in viral egress. It 
is possible earlier events are dysfunctional but are only revealed by impaired release. More 
evidence is needed to establish a role for NS1/2 in viral egress, if viral egress is related to 
persistence, and finally, a molecular mechanism for the role of NS1/2 in MNoV persistence.  
 
2.4.4 VP1 and tropism 
NoV tropism is incompletely understood (27). MNoV-1 non-structural proteins were 
detected in macrophages in Stat1-/- mice (41). Subsequently MNoV-1 has been cultured in 
primary macrophages and macrophage-like cell lines RAW264.7 and BV2 cells. Evidence for 
replication in intestinal epithelial cells is currently lacking, though other gastrointestinal viruses 
replicate predominately in these cells. More recently, both MNoV and HNoV are reported to 
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replicate in B cells (65, 66), but the definitive cells in vivo that support persistent viral replication 
are yet unknown.  
Among many phenotypic differences in mice (30, 34, 45), CR6 and CW3 replicate in 
different tissues in mice, and this is partially governed by VP1 (51). This argues either these 
strains have different cellular tropism, different tissue entry portals, and/or are trafficked 
differently. The observation that CR6 and CW3 replicate differently in BMDMs argues cellular 
tropism may be a major factor for tissue tropism. Direct detection of virus in situ has been 
problematic in WT mice. Therefore, further studies looking at MNoV growth in different 
macrophage or dendritic cell subsets will be critical to connect a role for VP1 determining 
cellular tropism in vivo. This will be important to mechanistically associate in vivo phenotypic 
differences between CR6 and CW3 to replication in different cell types. Identifying VP1 residues 
that correlate with cell tropism, then correlating these residues with in vivo phenotypes will be a 
powerful method to approach this question.  
Electroporated vRNA from pCR6 and pCW3 produced equivalent levels of virus at 12 
hours post infection, arguing the block for CR6 replication is at entry. However, CR6 had 
diminished levels of virus later in infection. Either CR6 replicates less robustly over time, or 
existing virus degrades over time. This may occur from a process intrinsic to CR6 or a 
degradative process in BMDMs that CR6 is uniquely susceptible to. It will be important to 
elucidate if this process is dependent on VP1 because it would provide evidence that VP1 
functions at a role downstream of entry to enhance viral growth in BMDMs.  
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2.5 Materials and Methods 
2.5.1 Cells and Media 
293T and RAW264.7 cells were maintained in DMEM with 10% FBS, 1% Pen/Strep, 
2mM L-Glutamine, and 10mM HEPES. To generate bone marrow derived macrophages 
(BMDM), mouse bone marrows were isolated and cultured on non-tissue-culture treated plate for 
seven days in BMDM media (Dulbecco’s Modified Eagle Medium, 10% fetal bovine serum, 5% 
horse serum, 10% CMG14-12 (67), 1x MEM nonessential amino acids, 1mM sodium pyruvate, 2 
mM L-glutamine). At day 7, adherent BMDMs were dissociated from the plate and frozen in 
fetal bovine serum with 10% DMSO. Cells were thawed and incubated three days when they 
were detached and plated at 1x10
5
 cells/24-well plate, and infected the next day for MNoV 
analysis.  
2.5.2 Cloning 
Cloning mutant MNoV done by site-directed mutagenesis using Phusion high-fidelity 
polymerase (New England BioLabs). Virus-encoding region of plasmids were fully Sanger-
sequenced prior to producing virus.  
2.5.3 MNoV 
Viral stocks. Stocks were generated as described (37). Briefly, infectious clones were 
transfected (Transit-LT1 (Mirus)) into 293T cells. 48 hours post transfection, plates were frozen 
and thawed to liberate virus (passage zero), centrifuged, and supernatants were inoculated onto 
RAW264.7 cells. 48 hours post infection (HPI), RAW264.7 cells were frozen, thawed, 
centrifuged, and supernatants were titered (passage one). Virus was further passaged on 
RAW264.7 cells at an MOI 0.01 PFU/cell, and clarified supernatant was ultracentrifuged at 
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30000 RPM for 3h. Pellets were resuspended in DMEM with 10% FBS and triply titered, 
constituting a passage two working stock of virus.  
Viability of mutant infectious clones. MNoV infectious clones with novel mutations 
were transfected as above, and frozen at 48 HPT. Virus titer was assessed using plaque assay.  
Virus infections. 5x10
4
 cells were seeded into each well of a 24 well plate the night 
before infection. MNoV was inoculated at indicated MOI onto cells in 200 μl final volume for 
30m on ice, then subsequently washed three times with complete media. 500 μl pre-warmed 
complete media was added back, immediately frozen for time 0, or incubated for the indicated 
time.  
Plaque assay. RAW264.7 cells were plated at 3x10
6
 cells/well in six well plates the night 
before the assay. Freeze-thawed samples were serially diluted on the day of the assay. 500μl of 
each dilution was inoculated onto RAW264.7 cell monolayers and rocked for one hour at room 
temperature. Inoculum was aspirated and cells were overlaid with methylcellulose media (MEM, 
10%FBS, 1% Pen/Strep, 2mM L-Glutamine, and 10mM HEPES). When plaques resolved in 2-3 
days, overlay was aspirated and replaced with 0.01% Crystal violet in 20% ethanol for greater 
than 1hr. Fixed monolayers were rinsed with water, dried, and plaques were counted.  
2.5.4 Mice and infections.  
C57BL/6J mice (stock number 000664) were purchased from Jackson Laboratories (Bar 
Harbor, ME) and housed at Washington University School of Medicine under specific-pathogen-
free conditions (45) according to university guidelines. Cages of male or female mice were 
inoculated with virus at 6 to 8 weeks of age by the oral route in a volume of 25 to 35 μl. A dose 
of 3x10
4
 PFU was used for all experiments, with one exception (1x10
6
 PFU; see Fig. 2.5E). Stool 
and tissues were harvested into 2-ml tubes (Sarstedt, Germany) with 1-mm diameter 
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zirconia/silica beads (Biospec, Bartlesville, OK). Tissues were flash frozen in a bath of ethanol 
and dry ice and either processed on the same day or stored at-80°C. 
2.5.5 Quantitative reverse transcription-PCR. 
RNA from stool was isolated using either an RNeasy Miniprep (Qiagen, Valencia, CA) 
or Quick-RNA Miniprep (Zymoresearch, Irvine, CA) kit. RNA from tissues was isolated using 
TRIzol (Life Technologies, Carlsbad, CA) according to the manufacturer’s protocol. Five μl of 
RNA from stool or 1 μg of RNA from tissue was used as a template for cDNA synthesis with the 
ImPromII reverse transcriptase system (Promega, Madison, WI). When evident in the melting 
curve analysis, DNA contamination was removed using the DNAfree kit (Life Technologies). 
MNoV TaqMan was performed as described previously (68). MNoV genome quantities from 
tissue samples were normalized to the house- keeping gene of ribosomal protein S29 (RPS29). 
SYBR green quantitative PCR for RPS29 was performed with the forward primer 5’-
AGCAGCTC TACTGGAGTCACC-3’ and reverse primer 5’-
AGGTCGCTTAGTCCAACTTAATG-3’ at a concentration of 0.2 μM in 1x Power SYBR green 
master mix (Life Technologies). Cycling parameters were identical to those for MNoV TaqMan 
with the exception of an additional melting curve analysis. 
2.5.6 Statistics and Software 
All statistics were calculated using Graphpad Prism software. ns = p>0.05, *= p≤0.05, 
**= p≤0.01, ***= p≤0.001, ****= p≤0.0001, all error bars signify standard error mean. 
Sequence alignments and analysis were performed in Geneious 9.1 (69). 
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Figure 2.1. NS1
CR6
 domain is necessary and sufficient for MNoV persistence. 
(A) Plasmid-derived pCR6 is persistently shed from stool but pCW3 is not persistently shed. 
Mice were infected 3x10
4
 PFU, stools collected at indicated time point, RNA was isolated from 
stool, and quantitative-RT-PCR for MNoV genomes was performed. Two-way ANOVA, 
Bonferroni’s post-test. n ≥4 for each time point.  
(B) Schematic of MNoV gene chimera for pCW3 and pCR6 used in this study. Red and blue 
indicate CR6 and CW3 sequences, respectively.   
(C) Mice were infected with indicated MNoV strains, stool collected 35 days post-infection, and 
MNoV genomes quantitated as in (A) . One-way ANOVA, Tukey’s post-test. 
(D) Single gene chimera were screened for their ability to establish persistent infection as in (B). 
1/Ct indicates inverse of threshold cycle and indicates relative quantity of MNoV genomes/stool. 
(E) Mice were infected with three independent preparations of pCW3-NS1/2
CR6
, and MNoV 
genomes were quantitated in stool at 35 days post-infection. 
(F) Comparison of MNoV genome shedding in stool for NS1/2 domain chimera during persistent 
infection. One-way ANOVA, Tukey’s post-test. 
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Figure 2.2. Mutation of aspartic acid residue 94 to glutamic acid in NS1
CW3
 is sufficient to 
confer persistence. 
(A) Alignment of first 117 residues of NS1 for CR6, CW3, and six other persistent strains of 
MNoV (accession numbers DQ223041, DQ223042, DQ223043, EU004672, EU004673, and 
EU004677 (30, 31)). 
(B) Ten residues in the NS1 domain differ between CR6 and CW3.  
(C) Mice were inoculated with indicated MNoV strains and stool collected at the persistence 
time points 28-36 days post infection. MNoV genomes were quantified by q-RT-PCR, showing 
mice from two independent experiments, one-way ANOVA, Tukey’s post-test.  
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Figure 2.3. MNoV NS1/2 mutants grow equivalently in RAW264.7 cells, but pCR6-NS1
CW3
 
release from cells is delayed.  
(A) Viral growth of persistent and non-persistent NS1/2 mutants in RAW264.7 cells. MOI 5.0 
left, MOI 0.05 right; virus was quantified by plaque assay and represented as plaque forming 
units/ml, n=3. 
(B) MNoV NS1/2 mutants infected RAW264.7 cells. Supernatant was removed at indicated 
times, microcentrifuged to remove debris, and cells and supernatant were frozen. Virus was 
quantified as in (A). Two-way ANOVA, Bonferroni’s post-test. MOI 5, n=3.   
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Figure 2.4. NS1/2 determines norovirus replication in colon, a major site of persistent 
infection, and VP1 determines viral replication in the spleen. 
(A-E) Tissues were harvested at indicated times in MNoV infected mice. RNA was isolated and 
MNoV genomes were detected by quantitative-RT-PCR.  
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(A) Tissues from pCR6 infected mice were harvested at day 35 post infection, n=2 with 5 mice 
per data point. One-way ANOVA, Tukey’s post-test. 
(B) Time course of pCW3 or pCR6 infection in proximal colon, spleen, and MLN. Two-way 
ANOVA, Bonferroni’s post-test, n=3 with 9 mice per data point. 
(C-D) Tissues were harvested from proximal colon, spleen, and MLN at day 7 post infection 
with indicated MNoV strains. One-way ANOVA, Tukey’s post-test, n=2 with 8 mice per data 
point. 
 (E) Proximal colon, MLN, spleen, and liver were harvested at days 3 and 35 from mice infected 
with pCR6-VP1
CW3 
at a dose of 1x10
6
 , n=2 with 6 mice per data point.  
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Figure 2.5. VP1 is the viral determinant for pCW3 growth in BMDMs 
(A-D) Virus quantitated by plaque assay, dotted line limit of detection of plaque assay. 
(A) Growth of pCR6 and pCW3 in BMDMs, MOI 0.5. Two-way ANOVA, Bonferroni’s post-
test, n=3.  
(B) Replication of CR6 and CW3 following electroporation of vRNA into BMDMs. Two-way 
ANOVA, Bonferroni’s post-test, n=3 
70 
 
(C) Screen of single gene or domain pCW3/pCR6 chimera for replication of virus 24 hours post 
infection, MOI 0.5. Upper dashed line represents average amount of virus for WT strain. One-
way ANOVA, Tukey's post-test, n=2. 
(D) Growth of indicated VP1 and VP1-domain chimera in BMDMs relative to WT pCR6 or 
pCW3. Non-significance was tested using two-way ANOVA, Bonferroni’s post-test, n=3 
 
 
  
71 
 
 
Chapter 3:  
Noroviruses coopt the function of host 
protein VAPA via an FFAT-motif mimic in 
nonstructural viral protein NS1/2 
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AM, Virgin HW. Noroviruses coopt the function of host protein VAPA for replication via a 
FFAT-motif mimic in nonstructural viral protein NS1/2. Under Review 
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3.1 Abstract 
The Norovirus genus contains important human pathogens but the role of host pathways 
in norovirus replication is largely unknown. MNoV provide model systems to study norovirus 
replication in cell culture and in small animals. The human norovirus nonstructural protein 
NS1/2 interacts with the host protein Vamp-Associated Protein A (VAPA), but the significance 
of the NS1/2-VAPA interaction is unexplored. Herein we report decreased MNoV replication in 
VAPA-deficient cells. VAPA was required for the efficiency of step(s) in the viral replication 
cycle after entry of viral RNA into the cytoplasm but before the synthesis of viral minus-sense 
RNA. The interaction of VAPA with viral NS1/2 proteins is conserved between murine and 
human noroviruses. NS1/2 of MNoV directly binds the Major Sperm Protein (MSP) domain of 
VAPA through its poorly conserved NS1 domain. Mutations within the viral NS1 domain that 
disrupted interaction with VAPA inhibited viral replication. Investigation of the structural basis 
for interaction between the NS1 and MSP domains revealed that the viral NS1 domain contains a 
mimic of the phenylalanine-phenylalanine-acidic-tract (FFAT)-motif that enables host proteins 
to bind to the VAPA MSP domain. The NS1/2-FFAT-mimic region interacted with the VAPA-
MSP domain in a manner similar to bona fide host FFAT motifs. Amino acids in the FFAT 
mimic region of the NS1 domain that are important for viral replication are highly conserved 
across MNoV strains. Thus, VAPA interaction with a norovirus protein that functionally mimics 
host FFAT motifs is important for MNoV replication. 
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3.2 Introduction 
Noroviruses are non-enveloped positive-sense single-stranded RNA viruses that primarily 
infect the gastrointestinal tract. Human noroviruses are a leading cause of epidemic 
gastroenteritis (1-3), but study of human noroviruses has been difficult due to the lack of robust 
culture systems, though recent work has demonstrated human norovirus replication in mice and 
cell lines (4, 5). NoVs are divided into genogroups GI-GVII. Of these, GI, GII, and GIV viruses 
cause human disease, and GV encompasses more recently discovered rodent NoVs, including 
MNoV (6). As MNoV replicates robustly in mice and cells, it serves as a powerful model for 
molecular studies of norovirus replication, tropism, and pathogenesis (7, 8). 
The norovirus genome encodes nine known proteins: seven non-structural (NS) proteins 
derived by proteolysis of the ORF 1 polyprotein (9), and two structural proteins, VP1 and VP2 
derived from ORFs 2 and 3 respectively (7). MNoV encodes the virulence protein VF1 from 
ORF4, which overlaps ORF2 and has not been found in human noroviruses (10). The N-terminal 
protein in the norovirus polyprotein, NS1/2, is comprised of three domains: NS1, NS2, and a 
putative transmembrane domain (11). The MNoV NS1 domain in isolation has a structured 
region preceded by an unstructured domain (11, 12). A single aspartic acid to glutamic acid 
difference within NS1 confers an altered conformation within the NS1 structured domain (12) 
and is associated with enteric tropism and the capacity of MNoV to persistently infect and be 
shed from the mouse intestine (13). NS2 contains a domain with a predicted structural 
resemblance to domains found in a variety of enzymes (14). Ectopically expressed NS1/2 from 
GI human norovirus (NS1/2
GI
) disrupts the Golgi apparatus and vesicular trafficking (15, 16) and 
is reported to interact with the host protein Vamp-Associated-Protein A (VAPA) (15). The role 
of VAPA interactions with NS1/2 during viral replication has not been defined.  
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VAPA is a type II endoplasmic reticulum (ER) resident protein that is conserved in 
eukaryotes (17). VAPA is comprised of a Major Sperm Protein (MSP) domain, a Coiled-Coil 
domain (CCD), and a transmembrane domain. Initially found to bind SNAREs (18-20), VAPA 
also binds a variety of client interacting proteins (17). Importantly, through the cytosolic MSP 
domain, VAPA interacts with client proteins primarily involved in lipid trafficking (17, 21-25). 
These proteins interact with VAPA-MSP via a phenylalanine-phenylalanine acidic tract (FFAT) 
linear motif (22, 26-29).  
VAPA performs important functions during infection as both microbes and antimicrobial 
host molecules target VAPA and its client proteins. VAPA and its paralog VAPB enhance the 
replication of Hepatitis C virus (30, 31), rhinoviruses (32), tombusvirus (33, 34), and the 
intracellular bacteria Chlamydia trachomatis (35, 36). Some of these microbes encode molecules 
that interact with VAPA, VAPB, and/or its client proteins, including HCV proteins NS5a and 
NS5b (30, 31), tombusvirus p33 (33, 34), and C. trachomatis IncD (35, 36). Several observations 
support the idea that VAPA and VAPA client proteins assist in organization of membranous 
structures critical for virus replication (37, 38), possibly by manipulating the lipid composition of 
these membranes (32-34). Furthermore, VAPA binds to the interferon stimulated genes IFITM3 
(39) and RSAD2 (40, 41), suggesting that VAPA may be involved in antiviral responses. 
Herein we defined the function and molecular basis of NS1/2-VAPA interactions during 
MNoV infection. Disruption of VAPA in permissive cells delayed MNoV replication due to 
effects occurring after viral entry but prior to synthesis of viral minus-sense RNA. The 
interaction between NS1/2 and VAPA was conserved between human norovirus and MNoV 
NS1/2 proteins. The NS1 domain of MNoV NS1/2 interacted with the MSP domain of VAPA. 
This interaction occurred independent of other cellular or viral proteins, and mapped to a short 
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region in the NS1 domain sharing features of the FFAT motif found in host proteins that also 
interact with the VAPA MSP domain. NS1 engaged VAPA MSP domain residues crucial for 
interaction with FFAT motifs found in VAPA client proteins. Mutagenesis of conserved amino 
acids in NS1 to abrogate VAPA interaction impaired recovery of infectious MNoV after 
transfection of permissive cells with plasmids encoding the viral genome. These data indicate 
that NS1/2-VAPA binding is critical for efficient MNoV replication and that this occurs through 
viral mimicry of the host FFAT motif by amino acids in the NS1 domain of the nonstructural 
NS1/2 protein. 
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3.3 Results 
 
3.3.1 MNoV replication is diminished in VAPA-deficient cells 
To test the hypothesis that MNoV replication benefits from the function of VAPA, we 
genetically engineered RAW264.7 cells deficient in VAPA expression (hereafter Vapa
-/-
) using 
CRISPR-Cas9. In two cloned Vapa
-/-
 cell lines, 3A11 and 1E6, frameshifts in the first 37 
nucleotides (Figure 3.1A) of coding sequence resulted in loss of VAPA protein expression 
(Figure 3.1B). Vapa
-/- 
cells infected with MNoV strain CW3 had 2.2x (1E6) or 4.0x (3A11) 
fewer NS1/2 positive cells by flow cytometry 18 hours post infection than wild type cells (Figure 
3.1E, F). We observed lower levels of replication of MNoV strains CW3 and CR6 in both Vapa
-/-
 
cell lines (Figure 3.1C). Vapa
-/-
 cells also had increased viability during MNoV infection (Figure 
3.1D). We also observed lower MNoV infectivity in BV2-Cas9 cells transduced with single 
guide RNAs targeting Vapa (Figure 3.1G). Reconstituting VAPA production in Vapa
-/- 
cells via 
lentivirus transduction (Figure 3.2A) increased the percent of cells expressing NS1/2 at 18 hours 
post infection by 2.7 fold (3A11) or 4.1 fold (1E6) compared to transduction with GFP (Figure 
3.2C, D). Expression of VAPA increased viral replication for the Vapa
-/- 
1E6 line (Figure 3.2B), 
but not the 3A11 cell line. These data together indicate that MNoV infectivity was enhanced by 
VAPA expression.  
To test the role of VAPA in mice, we attempted to engineer Vapa
-/-
 mice. We were able 
to generate two mutant lines by transient expression of Cas9 and Vapa targeted sgRNA (Figure 
3.3A). However, Vapa
+/-
 crosses produced no Vapa
-/-
 pups (Figure 3.3B), though we did detect 
two Vapa
-/- 
embryos at E14.5 (Figure 3.3C). We concluded mutation of Vapa led to embryonic 
lethality.  
 
77 
 
3.3.2 VAPA is important for an early post-entry step in norovirus replication 
To investigate the role of VAPA in MNoV replication, we analyzed non-structural 
protein expression by measuring NS1/2 protein levels in infected cells by western blot. Infected 
Vapa
-/- 
cells expressed lower levels of NS1/2 protein four and six hours after infection (Figure 
3.4A) with the difference diminishing later in infection. This supports a role for VAPA in early 
events of MNoV replication. Because VAPA is associated with efficient entry of an enveloped 
virus (39) as well as the function of endosomes (21, 39, 42) through which MNoV likely passes 
to establish infection (43-45), we tested whether impaired viral entry in Vapa
-/-
 cells accounted 
for decreased NS1/2 production and viral replication. We reasoned that transfection of viral RNA 
would bypass any effect of VAPA on viral entry and uncoating. After electroporating purified 
viral RNA into cells, we detected decreased NS1/2 levels in Vapa
-/- 
cells (Figure 3.4B), despite 
observing no difference in transfectability as measured by plasmid-driven GFP expression 
(Figure 3.4B, middle). These data indicate that VAPA plays a role in viral protein expression 
downstream of viral entry. After the viral RNA accesses the cytoplasm, NS1/2 protein can be 
produced by either translating in-coming plus-sense virion RNA or from viral plus-sense RNA 
transcribed from newly synthesized minus-sense RNA. Using strand-specific quantitative RT-
PCR (46), we observed delayed accumulation of both negative- and positive-sense MNoV RNA 
in Vapa
-/-
 cells (Figure 3.4C) indicating that production of NS1/2 is impaired prior to synthesis of 
new viral minus-sense RNA. Collectively, these observations support a role for VAPA 
downstream of viral RNA delivery into the cytosol, but upstream of minus-sense viral RNA 
synthesis. 
 
3.3.3 NS1/2 interaction with VAPA is conserved among norovirus strains 
Prior work showed that VAPA binds to human NoV NS1/2
GI
 (15). To determine the 
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evolutionary conservation of the NS1/2
GI
-VAPA interaction we tested NS1/2
MNoV
 interaction 
with VAPA. Consistent with published observation (15), Flag-tagged NS1/2
GI
 reciprocally co-
immunoprecipitated with HA-tagged VAPA (Figure 3.5A). Flag-tagged NS1/2
MNoV
 (strain CR6) 
immunoprecipitated weakly with VAPA (Figure 3.5A) and with NS4 as previously shown (47). 
To test for direct NS1/2-VAPA interaction using a system with which we could more 
easily map interactions, we assessed NS1/2 interaction with VAPA by mammalian 2-hybrid 
(M2H). In this assay, interaction between a “bait” and “prey” protein generates a luciferase 
signal. As previously reported (15, 23, 48), we detected VAPA interaction with itself, the host 
protein OSBP, and human norovirus NS1/2
GI
, validating use of M2H as an approach to assess 
VAPA interactions (Figure 3.5B). NS1/2
MNoV
 from either MNoV strain CW3 or CR6 interacted 
with VAPA (Figure 3.5B). We also detected interaction of NS1/2
MNoV
 with VAPB, a paralogue 
of VAPA (17) with 62% amino acid identity.  
 
3.3.4. VAPA interacts with NS1/2 during MNoV infection 
To test if VAPA interacts with NS1/2 during infection, we engineered MNoV to express 
a FLAG tag in NS1/2 (nucleotide 383) and used a previously described virus with a FLAG tag in 
NS4 (nucleotide 2600) (Figure 3.6A) (47). We selected NS4 for this experiment as it is known to 
bind NS1/2 (47). Both MNoV-NS1/2
FLAG
 and MNoV-NS4
FLAG
 replicated similarly to wild type 
virus (Figure 3.6B). FLAG-tagged viral proteins of appropriate molecular weight were expressed 
during infection (Figure 3.6A, top left). As expected, virus-derived FLAG-NS1/2 and FLAG-
NS4 localized with the viral replication complex (Figure 3.6C) (49). Having validated the use of 
FLAG-tagged viruses to study viral replication, we infected the BV2 microglial cell line with 
MNoV-NS1/2
FLAG
 and MNoV-NS4
FLAG
. Both FLAG-NS1/2 and FLAG-NS4 co-precipitated 
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with VAPA, but not NS7 or GAPDH (Figure 3.6D). Thus NS1/2, either independently or 
together with NS4, interacts with VAPA (47).  
 
3.3.5 NS1/2 interacts with FFAT-binding residues in VAPA MSP domain 
Many VAPA protein-protein interactions occur between the VAPA MSP domain and 
host cell proteins containing FFAT motifs. Structure-function analyses of FFAT-VAPA 
interactions support a model in which FFAT motifs from VAPA client proteins rest within a 
groove present on the surface of the VAPA-MSP domain (26, 28, 29). Within this groove, 
VAPA residues K50, K52, K94, M96, and K125 are critical for interaction with FFAT motifs. 
To test if these residues also engage NS1/2, we introduced the following mutations into VAPA: 
K50E/K52E, K94A/M96A, and K125E/R127E (Figure 3.7A). Each of these mutation pairs 
decreased VAPA interaction with NS1/2 (Figure 3.7A) as measured by M2H. To test if NS1/2 
interacts with sets of positively charged residues elsewhere in VAPA, we mutated additional 
sites in VAPA selected to have the sequence (H/R/K)X(H/R/K). Mutations K161E/H163E, 
H195E/R197E, and R202E/R204E had no effect on NS1/2-VAPA interaction (Figure 3.7A). We 
conclude that NS1/2 interaction specifically required positively charged residues within the 
VAPA MSP domain. 
To test if NS1/2 must interact with VAPA to rescue MNoV infectivity in Vapa
-/-
 cells, we 
reconstituted Vapa
-/-
 with VAPA that did (K161E/H163E, H195E/R197E, and R202E/R204E) or 
did not (K50E/K52E, K94A/M96A, and K125E/R127E) interact with NS1/2. VAPA variants 
that did not interact with NS1/2 failed to rescue MNoV infectivity in Vapa
-/-
 cells, while mutants 
that interacted with NS1/2 rescued MNoV infectivity (Figure 3.7B). This result is consistent with 
the model that VAPA must interact with NS1/2 to enhance MNoV infectivity. 
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 In work presented below, we found that the NS1 domain of NS1/2 is required for NS1/2-
VAPA interactions (Figure 3.8B). To map the physical interactions between NS1 and the VAPA-
MSP domain, we used NMR to analyze the chemical shift perturbations of the 
15
N-labeled 
VAPA-MSP domain (M8-M132 of VAPA) titrated with increasing amounts of unlabeled NS1 
(S28-R114 of NS1/2). This analysis revealed interactions between NS1/2 and four groups of 
residues on VAPA, K52-T54, C60-N64, K92-V97, and D123-L126 (Figure 3.7C). These groups 
of residues all mapped to the FFAT binding groove on a positively charged surface of the MSP 
domain. Furthermore, the VAPA residues that bind NS1/2 coincide with the FFAT-motif 
interaction surface on the MSP domain (26, 28). Using the same experimental approach, we did 
not observe any interactions of NS1 with the isolated coiled-coil domain (P133-S226 of VAPA, 
data not shown). 
We independently verified the role of the VAPA residues identified above in NS1/2-
VAPA interactions using M2H. To this end, we replaced selected amino acids in the VAPA MSP 
domain with either glutamate or alanine and tested for the interaction of these mutant molecules 
with NS1/2. No interaction was detected with glutamate or alanine substitutions at positions 
V51, K52, T54, K94, and K125 (Figure 3.7D). No interaction occurred after mutation of R62 to 
glutamate, but interaction was present with alanine at this site (Figure 3.7D). However, at 
positions K50, T53, V61, N64, M96, and R127 we observed interaction after replacing these 
residues with either glutamate or alanine (Figure 3.7D). These results indicate NS1/2 interaction 
with VAPA requires many of same residues FFAT motifs bind within a groove on the VAPA-
MSP domain (Figure 3.7E). 
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3.3.6 Residues 47-54 of MNoV NS1 are necessary for interaction with VAPA 
While the NS2 domain is well conserved within the NoV genus, NS1 is not (Figure 
3.8A). Accordingly, we predicted that the conserved NS2 domain contributed to the NS1/2 
interaction with VAPA. To test this hypothesis, we cloned a panel of N- and C-terminal NS1/2 
truncations. Surprisingly, the MNoV NS1 domain containing residues 1-131 was sufficient to 
interact with VAPA while the NS2 domain did not interact (Figure 3.8B). Furthermore, a region 
between residues 31-57 was necessary to interact with VAPA (Figure 3.8B).  
To define the specific NS1 residues interacting with VAPA-MSP, we analyzed the 
chemical shift perturbations of the NMR spectra of 
15
N-labeled NS1 (S28-R11 of NS1/2) with 
increasing amounts of unlabeled VAPA (M8-S226 of VAPA). The largest perturbations in NS1 
from both the CR6 and CW3 strains of MNoV were observed for a core of interacting residues 
centered on Y47-Q53 (YMTPPEQ) (Figure 3.9A, B). A longer sequence encompassing residues 
I45 to A61, showed consistent but smaller perturbations (Figure 3.9A, B). The VAPA interacting 
residues are predominantly within the segment K26-P57 that shows a highly dynamic 
conformation in isolated NS1 (50). The last few interacting residues of the core residues of NS1 
that interact with VAPA are in the structured domain of NS1 (G58-R114) (50). There are no 
observable amides in prolines; hence, no data were available for P50, P51, and P57. 
To test the importance of this core of interacting residues, we carried out experiments 
with three mutant forms of NS1, NS1-CR6
M48G
, CW3
T49G
, and CW3
E52K
. The Heteronuclear 
Single Quantum Coherence (HSQC) spectra obtained for mutants were similar indicating that 
these mutations did not destabilize tertiary structures (data not shown). NS1-CW3
T49G
 and 
CW3
E52K
 mutations decreased binding to VAPA to undetectable levels, while NS1-CR6
M48G
 
interacted with VAPA (Figure 3.9B).  
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3.3.7 MNoV NS1 contains a mimic of host FFAT domains 
Since this core domain of NS1 interacted with the MSP domain of VAPA, and the FFAT 
motif is responsible for interactions of host proteins with this same domain, we considered the 
possible relationship of this NS1 region and FFAT motifs. Generally, FFAT motifs contain a 
core sequence containing a bulky aromatic residue flanked N- and C-terminally by acidic 
residues (22, 27). Similar to FFAT motifs, NS1/2 encodes acidic residues (residues 40-44, 52, 
54) surrounding tyrosine 47 (Figure 3.9C). This sequence is conserved across MNoV strains 
(Figure 3.9C, Figure 3.10), though positions 45, 46, and 48 are variable. The strong conservation 
of certain amino acids in this region suggested that the motif is functionally important. 
To test which residues within this domain contribute to interaction with VAPA, we 
introduced single residue mutations and assessed their effect by M2H analysis. For positions in 
the N-terminal acidic segment, mutations E40A, E40K, E42A, E42K, D43A, D43K, E44A, and 
E44K blocked NS1/2-VAPA interaction, while S41G maintained detectable interaction (Figure 
3.9D). Within the FFAT-like core segment, Y47A, Y47G, T49A, and T49G ablated NS1/2 
interactions with VAPA. Residues at positions 45, 46, and 48 are variable across MNoV strains 
(Figure 3.9C, Figure 3.10). To test the function of amino acids in these positions, we introduced 
variants observed in other MNoV strain, including V45A, V45I, N46C, N46D, M48A, and 
M48L, as well as variants not observed in MNoV isolates, including V45G, N46G, M48D, 
M48I, and M48G. Mutations at these positions did not disrupt interaction, suggesting that the 
interaction is preserved for sequences that vary in these positions across strains (Figure 3.9D). 
For C-terminal acidic residues, E52K mutation disrupted the interaction, but E54K maintained 
interaction. Additionally, mutations outside of this region including H69L, D121G, and D131G 
did not prevent interaction (Figure 3.9D).  
Therefore, residues in the S40-E54 region of NS1/2 were necessary for interaction with 
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VAPA. The 1) chemical nature of the amino acids present (acidic, bulky aromatic), 2) their 
positions, 3) their importance for binding VAPA, 4) the interaction of this region with the region 
of VAPA that binds to FFAT motifs in host proteins, 5) the conservation of the critical amino 
acids across strains and 6) the arrangement of the acidic amino acids surrounding and FFAT-like 
core argue that this region of NS1 is mimicking host FFAT motifs as a basis for interacting with 
the MSP domain of VAPA.  
 
3.3.8 NS1/2-VAPA interactions are required for recovery of MNoV from 
infectious clones 
To determine the importance of the NS1/2-VAPA interaction and specific amino acids in 
the NS1/2 FFAT-like domain for MNoV growth we assessed the effect of mutations in NS1/2 
using an infectious molecular clone of the virus. Mutations were introduced in a plasmid 
encoding the CR6 viral genome and recovery of infectious virus was assessed after transfection 
of the plasmid into permissive cells. We noticed three patterns of recovery of infectious virus in 
these experiments (Figure 3.11A): (i) some NS1/2 mutations had no discernable effect on virus 
recovery (V45G, V45A, V45I, N46D, M48A, M48L, H69L, D121G, and D131G); (ii) some 
NS1/2 mutations resulted in variable recovery (S41G, N46G, M48I, M48D, and E54K); (iii) 
some NS1/2 mutations completely eliminated virus recovery (E40A, E40K, E42A, E42K, D43A, 
D43K, E44A, E44K, Y47G, Y47A, M48G, T49G, T49A, and E52K). We saw similar patterns of 
virus recovery after insertion of mutations into NS1/2 in the CW3 genome with the following 
exceptions. NS1/2 mutations S41G, N46C, M48I, M48D, and E54K resulted in consistent 
recovery of virus; E40A, D43A mutations resulted in variable virus recovery; I45G mutation 
completely prevented virus recovery (Figure 3.11B).  
Importantly, this mutational analysis of the NS1 domains of two strains of MNoV 
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revealed a strong correlation between mutations that perturbed VAPA interaction (Figure 3.11C 
top panel) and those which diminished recovery of virus (Figure 3.11C bottom two panels). Side-
chains for residues that were critical for recovery of virus primarily mapped to a sequence 
showing highly dynamic behavior in free NS1 and a few N-terminal residues of the NS1 
structured domain (50) (Figure 3.11D). The specificity of the relationship between side-chain 
and function within this region is strikingly revealed by comparing the role of the tyrosine at 
position 47, which was important for virus recovery, and the immediately adjacent methionine at 
position 48 at which multiple amino acids substitutions were tolerated.  
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3.4 Discussion 
 
3.4.1 Summary 
In this study, we define the importance of the host protein VAPA and its interaction with 
the viral nonstructural protein NS1/2 in replication of MNoV. We confirmed the previously 
identified interaction between a human norovirus NS1/2 protein and VAPA (15) and found that 
this interaction is shared with the NS1/2 proteins of two MNoV strains. Using a variety of 
approaches including analysis of the interaction of the proteins in vitro and in cells, we delineate 
the structural basis for the interaction between VAPA and NS1/2 and used these data to test for 
the importance of specific amino acids in NS1/2 for viral replication and for the interaction 
between VAPA NS1/2. These studies support the concept that VAPA is a pro-viral host protein 
for MNoV infection, and that interaction between NS1/2 and VAPA is important for viral 
replication. Remarkably, the MNoV NS1 domains appear to mimic host VAPA-binding proteins 
through the conservation of a region that mimics host FFAT domains present in VAPA MSP 
domain-interacting proteins.  
 
3.4.2 Norovirus mimicry of host FFAT motifs 
Mimicry of host molecules and motifs is a pervasive evolutionary theme enabling 
microbes to hijack host processes (51). While efforts have been made to predict mimicry on 
large-scale (50, 51), detecting structural and/or functional domain mimics requires validation 
through detailed studies of individual microbial molecules. For other microbial proteins involved 
in targeting VAPA mimicry via an FFAT motif has not been reported. It will be interesting to 
determine whether FFAT domain mimicry is a common strategy for microbial proteins that 
target VAPA. If so, small molecules that target this interaction surface may have antiviral or 
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antimicrobial properties for multiple microbes that similarly bind VAPA. In this regard, it is 
important that FFAT motifs tolerate variation at many positions (22, 27), are relatively short, and 
are unstructured in solution (26), potentially enabling viruses or other organisms to evolve 
strategies to target VAPA. It is interesting that much of the region of MNoV NS1/2 that contains 
the FFAT mimic is unstructured in the purified NS1 domain (50). It seems possible that the 
interaction of these domains with the MSP domain of VAPA is somehow enhanced by the 
unstructured nature of this region.  
This mimicry likely arose from convergent evolution, exploiting the partially unstructured, 
highly diverging, and evolving sequence of the NS1 domain. The observation that the NS1 
domain, including the MNoV NS1-FFAT mimic, is poorly conserved across NoV genogroups 
bolsters this idea. Future work revealing how NS1 from HNoV interacts with VAPA and how 
broadly conserved this interaction is across a comprehensive set of NoV strains will test this 
hypothesis. Furthermore, no naturally occurring variants of MNoV disturbed NS1/2-VAPA 
interaction. This introduces the possibility that the NS1/2-VAPA interaction has undergone 
purifying selection in MNoV.  
The greatest similarity of the MNoV NS1/2 sequences to host FFAT motifs was 
identified in the N-terminal and C-terminal portions of the motif. The core sequence was less 
similar, notably lacking a phenylalanine followed by D/E, instead encoding a tyrosine without a 
flanking acidic residue. The third position of host FFAT motifs (the second of the two Phe 
residues defining the motif in host proteins) tolerates wide range of residue substitutions without 
loss of functionality. Similarly, both NMR and M2H experiments with the NS1 M48G mutant 
are consistently tolerant of variability at this site. Nonetheless, at the structural level, the binding 
mode of NS1/2 to VAPA showed remarkable similarity to the binding of host FFAT motifs to 
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VAPA, for example by interacting with specific VAPA amino acids in the MSP domain. It is 
therefore interesting that the core portions of host and norovirus FFAT motifs differs in some 
regards, suggesting that there may be specific properties of the interaction that are unique to the 
viral FFAT motif. Future work revealing the molecular basis of the interaction between human 
norovirus NS1/2 and VAPA and examining the conservation of relevant amino acids across 
norovirus genogroups and strains will be of interest. 
 
3.4.3 Role of VAPA in norovirus replication 
Our work does not reveal the mechanism by which VAPA participates in the viral life 
cycle. However, it is clear that the stages of viral replication after entry and before minus-sense 
viral RNA synthesis are affected by VAPA. We have considered two non-mutually exclusive 
possibilities for the function of the NS1/2-VAPA interaction at this early stage of viral 
replication. First, the NS1/2-VAPA interaction could localize NS1/2 to the ER in order to initiate 
formation of the membranous viral replication compartment. Notably, the advantage afforded by 
direct interactions of viral proteins with VAPA and VAPB proteins has been reported for 
Hepatitis C Virus (30, 31) which also required rearrangements of intracellular membranes to 
create a replication complex. MNoV NS1/2 is associated with the ER when expressed 
independent of other viral proteins (49, 52), and VAPA is an ER-resident protein, suggesting the 
possibility of a role for VAPA in NS1/2 localization. It is notable that the NS1 domain that 
contains the FFAT motif mimic would be the first portion of the polyprotein synthesized from 
viral plus-sense RNA, and could therefore contribute to coordination of initial steps of viral 
replication at the ER prior to synthesis and processing of the rest of the viral polyprotein.  
Second, it is also conceivable that the interaction of NS1/2 with VAPA alters lipid 
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metabolism through competition for the interactions between VAPA and VAPA-client proteins 
that also have FFAT domains. In this regard, it is not known whether any of the specific 
processes carried out by VAPA client proteins are important for enhancing or inhibiting 
norovirus replication. Answering this question is likely to be complex since VAPA interacts with 
multiple client proteins such as OSBP and CERT and to be involved in a range of processes in 
the cell including non-vesicular lipid transfer (23, 25, 53), lipid metabolism (53, 54) and is 
present at membrane contact sites (55-59). Nevertheless, the conservation of a structural motif 
related to the FFAT motifs found in proteins that interact with the MSP domain of VAPA 
indicates the value of dissecting the possible role of VAPA-dependent functions in the viral life 
cycle and of the impact of NS1/2 function on VAPA-dependent proteins.  
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3.5 Materials and Methods 
 
3.5.1 Cells and Media 
293T, BV2, and RAW264.7 cells were maintained in DMEM with 10% FBS, 1% 
Pen/Strep, 2mM L-Glutamine, and 10mM HEPES. The Genome Engineering and iPSC Center 
(St. Louis, MO) engineered VAPA-knockout RAW 264.7 cell lines 1E6 and 3A11. Briefly, 
guide RNAs (5'-GGCGAAGCACGAGCAGATCCTGG-3' and 5'-
GATCTGCTCGTGCTTCGCCATGG-3') targeting VAPA were transfected into RAW 264.7 
cells transiently expressing Cas9. Cells were clonally selected and verified for disruption of 
endogenous locus via the Cel-1 nuclease assay, then deep sequenced to identify frameshift 
mutations.  
3.5.2 Cloning 
NS1/2 from MNoV strains CR6 and CW3 infectious clones (13), and GI (NC_001959), 
as well as VAPA (NM_013933), were cloned into Gateway vector pDONR221 (Life 
Technologies), and subcloned using Gateway recombination and expression vectors. Cloning 
mutant MNoV done by site-directed mutagenesis using Q5/KLD mix or Phusion (New England 
BioLabs) and as described previously (60). The generation of the MNoV-NS4
FLAG
 infectious 
clone was described previously (47), and MNoV-NS1/2
FLAG
 was generated similarly with FLAG 
tag nucleotide sequence inserted after nucleotide 383 of the MNoV-1 genome by overlapping 
PCR. 
3.5.3 MNoV 
Viral stocks. Stocks were generated as described (13). Briefly, infectious clones were 
transfected (Transit-LT1 (Mirus)) into 293T cells. 48 hours post transfection, plates were frozen 
and thawed to liberate virus (passage zero), centrifuged, and supernatants were inoculated onto 
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RAW264.7 cells. 48 hours post infection (HPI), RAW264.7 cells were frozen, thawed, 
centrifuged, and supernatants were titered (passage one). Virus was further passaged on 
RAW264.7 cells at an MOI 0.01 PFU/cell, and clarified supernatant was ultracentrifuged at 
30000 RPM for 3h. Pellets were resuspended in DMEM with 10% FBS and triply titered, 
constituting working stock of virus (passage two). The recovery of infectious FLAG-tagged 
MNoV was described previously (61). Briefly, infectious clones were transfected in BSRT7 cells 
infected with fowlpox virus expressing T7 RNA polymerase at MOI 0.5 to 1. 24 hours post 
transfection, MNoV were released by freeze-thawing plates. Then BV2 cells were inoculated 
with the recovered viruses at MOI 0.01 TCID50 per cell, and viral stocks (passage one) were 
generated by freeze thawing the infected cells upon appearance of cytopathic effect and spinning 
down of cell debris at 4000 RPM for 5 minutes. The stability of FLAG tag insertions at passage 
three was verified by RT-PCR and sequencing of the viruses at relevant genomic locations, and 
Western Blot against FLAG tag using infected lysate (data not shown). 
Viability of mutant infectious clones. MNoV infectious clones with novel mutations 
were transfected as above, and frozen at 48 HPT. Virus titer was assessed using plaque assay.  
Virus infections. MNoV was inoculated at indicated MOI into cells in suspension for 
30m on ice, and subsequently washed three times with complete media. For growth curves and 
FACS analysis, cells were plated and harvested at indicated times post infection.  
Plaque assay and TCID50. RAW264.7 cells were plated at 3x10
6
 cells/well in six well 
plates the night before the assay. Freeze-thawed samples were serially diluted on the day of the 
assay. 500μl of each dilution was inoculated onto RAW264.7 cell monolayers and rocked for one 
hour at room temperature. Inoculum was aspirated and cells were overlaid with methylcellulose 
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media (MEM, 10%FBS, 1% Pen/Strep, 2mM L-Glutamine, and 10mM HEPES). When plaques 
resolved in 2-3 days, overlay was aspirated and replaced with 0.01% Crystal violet in 20% 
ethanol for greater than 1hr. Fixed monolayers were rinsed with water, dried, and plaques were 
counted. TCID50 was determined on BV2 cells as described previously (62). 
3.5.4 Flow cytometry  
Cells were infected as above. At indicated time, supernatant was collected for viral 
titering. Cells were washed once in PBS, scraped and transferred to a U-bottom 96well plate. All 
subsequent steps occurred at RT. Samples were incubated with fixable live/dead stain for 10 
minutes, pelleted, and resuspended in 4% formaldehyde. After 10 minutes of fixation, cells were 
permeabilized in 0.2% Triton-X100 in PBS (PBS-T) for 20 minutes at RT or overnight at 4°C. 
Cells were then blocked (PBS-T, 3%FBS, 1% normal mouse serum, 1% normal goat serum) for 
10 minutes, and incubated with 1:5000 dilution of polyclonal anti-NS1/2 Rabbit sera (Vernon 
Ward) for one hour. After three washes in PBS-T, cells were stained for 30-60 minutes with 
1:500 dilution of anti-Rabbit secondary antibody conjugated to either Dylight 649 (BioLegend, 
406406) or PE (Caltag, L43004), or anti-FLAG PE (BioLegend, 637310). After three PBS-T 
washes, cells were resuspended in PBS-T with 3% FBS passed through a cell strainer, and 
analyzed on an LSR II or FACS Calibur flow cytometer. All analysis was performed on FlowJo 
(Treestar, OR).  
Cell Viability. Scraped cells were resuspended in 1:500 Fixable Aqua Live/Dead stain 
(Thermo Fisher), incubated at RT for 10m, microcentrifuged, then resuspended in fixative.  
3.5.5 Confocal microscopy 
2 x 10
5
 BV2 cells were seeded on glass coverslips and were infected at MOI 1 
TCID50/cell. At 12 hours post infection, cells were fixed with 4% paraformaldehyde (PFA) in 
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PBS, quenched with 0.1M Glycine in PBS and permeabilized with 0.2% Triton X-100 in PBS. 
After blocking with 0.1% TWEEN 20 in PBS (PBST) containing 1% BSA and 1% Normal Goat 
Serum (Sigma Aldrich), mouse monoclonal anti-FLAG M2 (Sigma Aldrich) and rabbit 
polyclonal anti-NS7 antibodies were diluted 1:1000 in blocking solution and added to cells at 
room temperature for 1 hour. After washing three times with PBST, Goat anti-mouse IgG Alexa 
Fluor® 488 conjugate and Goat anti-rabbit IgG Alexa Fluor® 546 were added at dilution of 
1:1000 in PBST. After incubation at room temperature for 1 hour protected from light, the 
coverslips were washed three times with PBST before mounting with Mowiol medium 
containing DAPI (4′,6-diamidino-2-phenylindole) stain. The confocal images were taken using a 
Zeiss 510 Meta laser confocal microscope. 
3.5.6 Lentivirus 
Lentiviral constructs, packaging plasmid, and VSV-G were transfected (TransIT-LT1, 
Mirus) into ~70% confluent 293T cells. 60 hours post-transfection, supernatant was filtered (0.45 
micron) and inoculated onto ~5% confluent RAW 264.7 cells. The next day, media was replaced 
with complete media. 72 HPI, media was replaced with media with puromycin (5ug/ml). Cells 
were subsequently maintained in puromycin. 
3.5.7 Immunoprecipitation 
For ectopic expression, ~85% confluent 293Ts were transfected (TransIT-LT1, Mirus). 
48 hours later, cells were washed once with PBS. Cells were washed once with PBS and lysed 
(50mM Tris-HCl (pH 7.5), 125mM NaCl, 1.5mM MgCl2, 5% Glycerol, 0.2% NP-40, fresh 
Protease Inhibitor Cocktail III (Roche)), and kept on ice. Lysates were passed through 29G 
needle five times, rested 5 minutes, repeated, then spun 16000 xg at 4°C. An aliquot of 
supernatant was removed for analysis of lysate. The remainder of supernatant was incubated with 
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Protein A/G beads (Santa Cruz) resuspended in lysis buffer for 30 minutes, then spun 1000 xg 
for one minute. Supernatant was incubated with 1μg/mL antibody for one hour, after which 50 μl 
Protein A/G beads were added and rotated overnight at 4°C. Beads were washed four times with 
one mL lysis buffer, then boiled with two times in laemmeli buffer for two to three minutes, and 
supernatant was frozen prior to analysis.  
For anti-FLAG immunoprecipitation, BV2 cells were infected at MOI 10 TCID50/cell and 
were harvested at 8 hours post infection. Cells were washed three times with cold PBS before 
lysis with 50mM Tris-HCl pH7.4, 150mM NaCl, 1mM EDTA, 2 mM MgCl2, 1% Triton X-100, 
1% v/v Protease Inhibitors Cocktail (Promega), 0.1% benzonase (Sigma Aldrich). The lysates 
were incubated on ice for 30 minutes to allow benzonase digestion of DNA and RNA, before 
spinning down for 10 minutes at 15000 RPM at 4°C. The supernatants were collected and the 
protein concentrations were determined by BCA assay (Thermo Fisher). The ANTI-FLAG M2 
affinity agarose gel (Sigma Aldrich) was pre-washed twice with TBS buffer (50mM Tris-HCl 
pH7.5, 150mM NaCl. 2 mg total protein in 1ml lysis buffer was loaded to 40 µl ANTI-FLAG 
agarose and incubated at 4°C overnight with rotation. After removing the unbound protein by 
centrifugation at 5000 x g for 30 seconds at 4°C and three more washes with TBS buffer, the 
bound proteins were eluted by adding 50 µl 2X SDS-PAGE sample buffer and heating at 95°C 
for 3 minutes.  
3.5.8 Western Blot 
Laemmeli buffer was added to samples, then boiled 10-15 minutes. Protein was resolved 
on either 10% or 4-20% (Bio-Rad) SDS-PAGE Tris-Glycine gels. Protein was transferred semi-
dry to PVDF membranes, blocked with 5% milk in TBS-tween, then incubated with antibody 
overnight at 4°C. Membranes were triply washed with TBS-tween, then incubated for an hour 
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with HRP-conjugated secondary antibody. After three TBS-tween washes, membranes were 
incubated with ECL or ECL2 reagent (Pierce), and signal was detected on film (MidSci). For 
densitometry, NS1/2 band density was calculated using ImageJ, normalized to Gapdh band 
density, then reported as a ratio to WT from each respective time point. 
3.5.9 Antibodies 
Polyclonal rabbit NS1/2 antisera was a kind gift from Vernon Ward. Anti-VAPA clone 
K-15 (sc-48698) was obtained from Santa Cruz Biotechnology. Anti-FLAG (M2) (Sigma 
Aldrich) anti-HA (H9658, Sigma Aldrich) were conjugated to HRP using Lightning-Link HRP 
Antibody Labeling Kit (701-0000, Innova Bioscience), and anti-Strep-tag II-HRP was acquired 
(71591-3, Novagen). Gapdh-HRP (G9295-25UL, Sigma Aldrich), and anti-actin (A5316, Sigma 
Aldrich) were used for normalization. Anti-VP16 (sc-7546) and anti-Gal4 BD (sc-510) (Santa 
Cruz Biotechnology) were used for M2H expression validation. Secondary antibodies obtained 
from Jackson Immunoresearch: Anti-Rabbit HRP (111-035-003), Anti-Goat-HRP (705-035-
003), and Anti-mouse HRP (115-035-146).  
3.5.10 Strand-specific qPCR 
Cells were infected as above. At each time point post infection, cells were lysed and total 
cellular RNA was extracted using GenElute™ mammalian total RNA Miniprep Kit (Sigma 
Aldrich). Quantities of genomic positive/negative RNAs were determined using strand-specific 
RT-qPCR according to (46) with the following changes: 100ng total RNA was used in each RT 
reaction and 5µl of cDNA was used for genomic negative qPCR. The mean of log10 gEq/ng total 
RNA of mock-infected cells was used as the limit of detection (LOD). The results were obtained 
using ViiA™7 Real-Time PCR System. 
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3.5.11 Mammalian 2-Hybrid 
Checkmate Vectors (Promega) pACT (prey) and pBIND (bait) were converted to 
Gateway destination vectors and genes were subcloned used Gateway LR reactions (Life 
Technology). Subsequent M2H analysis was performed as described previously (63). In brief, 
7.5 fmol Bait and Prey plasmids with 100ng pG5 reporter plasmid were incubated with 40 μl 
Optimem (Life Technology) and 2 μl Transit-LT1. DNA-reagent complexes were added to 293T 
cells 50-75% confluent. 48-51h post transfection, cells were lysed using Passive Lysis Buffer, 
and luminescence was measured using Dual-Luciferase Reporter Assay (Promega) on an 
Opticomp II (MGM Instruments) luminometer. Firefly luciferase luminescence was reported as 
percentage of Renilla luciferase for each sample. All data shown are n≥3, determined normally 
distributed, comparing the greater of bait- or prey-only with bait+prey. Fold-change calculated 
from average of bait+prey/average highest background (bait or prey). 
3.5.12 Vapa Mutant Mouse  
Day 0.5 B6/J inbred embryos underwent pronuclear microinjection with gRNA and Cas9-
mRNA, then embryos were implanted in surrogate mothers as described (64). Mutations in live 
born pups were identified by isolating tail DNA, PCR amplifying the Vapa targeted locus, and 
Sanger sequencing. Genotypes were verified by TOPO-TA (Life Sciences) cloning the 
amplicons and Sanger sequencing.  
Genotyping. Mutant line 1: Primers were designed to amplify Vapa locus (F-
CTGCTGAGCGGACAGGCTG, R- CGCAAGATGGCGGCGGAG), wt: 500 bp, deletion: 440 
bp. Mutant line 2: Genotyping to detect single base pair insertion was designed as in (65). In 
brief, primers designed to detect specifically WT (F- GGCCCCGTCCTAGAGCTCCG, R- 
ATATGATAGTAACTATCCAGGATCTGCTCGTGCTACGC) amplified a 180 bp product. 
Primers designed to detect mutant (F- GGCCCCGTCCTAGAGCTCCG, R- 
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AAAAACCAGGATCTGCTCGTGCTTAGG) amplified a 159 bp product. Genotyping was 
verified by PCR amplifying locus and Sanger sequencing.  
3.5.13 NMR 
 Protein Sample Preparation for NMR experiments. We purified natural abundance and 
15
N-labeled N-terminally His6-tagged 28-114 domain of MNoV NS1/2 protein as described (12). 
Single amino acid mutations were introduced with QuickChange approach. We also constructed 
E. coli expression plasmids and purified three fragments of natural abundance and 
15
N-labeled 
N-terminally His6-tagged murine VAPA protein. The isolated VAPA MSP domain, residues 8-
132, gave excellent NMR spectra. Similarly, MSP domain with the following linker and coiled-
coil domain, residues 8-226, gave excellent NMR spectra. As expected, VAPA residues 8-226 
formed stable dimers in solution, confirmed by a size exclusion chromatography and diffusion 
NMR experiments. The third VAPA fragment consisting of residues 133-226, also showed 
dimeric size in solution, and NMR spectra indicative of contributions from α-helical and 
disordered segments. Protein samples were concentrated and dialyzed extensively against 10 mM 
KH2PO4, 20 mM KCl, pH 7.0. Final concentrations of NS1/2 28-114 (ε280=13,940 M
-1
cm
-1
) and 
VAPA (ε280=8,250 M-1cm-1) were 0.4 mM and 1.6 mM, respectively, as determined 
spectrophotometrically. All samples contained reducing reagent 1 mM dTECP, 5% D2O for lock 
signal and 0.5 mM DSS as a chemical shift reference.  
 Chemical Shift Perturbation Experiments. After 24 h dialysis against the same buffer 
solution, protein samples were mixed by step-wise addition of VAPA solution. Each addition 
was followed by NMR experiments, carried out at 25 ˚C on a Bruker 600 MHz instrument 
equipped with a cryoprobe. First, for each 
15
N-labeled NS1/2 protein construct, 
15
N-
1
H HSQC 
spectrum was recorded for a NS1/2 protein only. Following 5-6 spectra were recorded after each 
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addition of natural abundance VAPA, typically from 0.5 to 10.0-fold excess over the NS1/2 
concentration present. NMR data were processed (Topspin 3.2, Bruker), and the chemical shift 
perturbations were analyzed using NMRFAM-SPARKY (66). The chemical shift assignments 
for NS1/2 (Accession nos. 19439, 19444) and closely related human VAPA (Accession 
no. 7025) are available in BMRB database. The specific values of chemical shifts for the buffer 
conditions and protein constructs used here were verified by acquisition of standard suite of 
triple resonance experiments on 
13
C/
15
N–labeled samples. Chemical shift perturbations on 15N-
labeled VAPA were analyzed in analogous fashion, except that initial concentrations of VAPA 
and NS1/2 were 0.1 mM and 2.2 mM, respectively and the step-wise addition of NS1/2 was 
performed. Figures show combined difference of 
1
H and 
15
N chemical shifts observed between 
zero and the highest concentration of unlabeled protein used. The combined differences in ppm 
units were calculated as ∆𝛿 =  √{1
2
[(∆𝛿𝐻)2 + (
∆𝛿𝑁
5
)2]}, and hereafter they are referred to as 
chemical shift perturbations. The threshold for perturbations interpreted as specific protein-
protein interactions was set at a value of four standard deviation above the mean perturbation 
excluding the highest perturbations for each data set.  
3.5.14 Statistics and Software 
All statistics were calculated using Graphpad Prism software. ns = p>0.05, *= p≤0.05, 
**= p≤0.01, ***= p≤0.001, ****= p≤0.0001, all error bars signify standard error mean. 
Sequence alignments and analysis were performed in Geneious 9.1 (http://www.geneious.com) 
(67). Molecular graphics were produced using UCSF Chimera (68). 
 
98 
 
3.6 Acknowledgments:  
We thank the Alvin J. Siteman Cancer Center at WUSM and Barnes-Jewish Hospital in 
St. Louis, MO, for the use of the Genome Engineering and iPSC Center. Mice were generated 
using the WUSM Department of Pathology Microinjection Core. We thank Megan Baldridge, 
Robert Orchard, Craig Wilen, and Donna MacDuff, for intellectual contributions and reviewing 
the manuscript, Vernon Ward for the generous gift of anti-NS1/2 rabbit sera, and Darren 
Kreamalmeyer for handling and breeding mice. 
The Siteman Cancer Center was supported in part by NCI Cancer Center Support Grant 
P30CA091842. The Washington University School of Medicine (WUSM) Department of 
Pathology Microinjection Core was supported by P30AR048335. HWV was supported by U19 
AI 109725. BTM was supported by NCI-NIH award F31CA177194-01. TJN was supported by 
NIH training grant 5T32A100716334 and postdoctoral fellowships from the Cancer Research 
Institute and American Cancer Society. IG was supported by funding from the Wellcome Trust 
(ref: 097997/Z/11/Z) and the Biotechnology and Biological Sciences Research Council (ref: 
BB/N001176/1). JE was supported by a Churchill Scholarship. The funders did not influence 
study design, data collection or interpretation, or preparation of the manuscript. Neither the 
authors nor this study represent the official views of the funding agencies.  
  
99 
 
3.7 References 
1. Atmar RL, Estes MK. 2006. The epidemiologic and clinical importance of norovirus 
infection. GastroenterolClinNorth Am 35:275-290, viii. 
2. Hall AJ, Lopman BA, Payne DC, Patel MM, Gastanaduy PA, Vinje J, Parashar UD. 
2013. Norovirus disease in the United States. Emerg Infect Dis 19:1198-1205. 
3. Patel MM, Hall AJ, Vinje J, Parashar UD. 2009. Noroviruses: a comprehensive 
review. J Clin Virol 44:1-8. 
4. Taube S, Kolawole AO, Hohne M, Wilkinson JE, Handley SA, Perry JW, Thackray 
LB, Akkina R, Wobus CE. 2013. A mouse model for human norovirus. MBio 4. 
5. Jones MK, Watanabe M, Zhu S, Graves CL, Keyes LR, Grau KR, Gonzalez-
Hernandez MB, Iovine NM, Wobus CE, Vinje J, Tibbetts SA, Wallet SM, Karst SM. 
2014. Enteric bacteria promote human and mouse norovirus infection of B cells. Science 
346:755-759. 
6. Zheng DP, Ando T, Fankhauser RL, Beard RS, Glass RI, Monroe SS. 2006. 
Norovirus classification and proposed strain nomenclature. Virology 346:312-323. 
7. Thorne LG, Goodfellow IG. 2014. Norovirus gene expression and replication. J Gen 
Virol 95:278-291. 
8. Karst SM, Wobus CE, Goodfellow IG, Green KY, Virgin HW. 2014. Advances in 
Norovirus Biology. Cell Host Microbe 15:668-680. 
9. Sosnovtsev SV, Belliot G, Chang KO, Prikhodko VG, Thackray LB, Wobus CE, 
Karst SM, Virgin HW, Green KY. 2006. Cleavage map and proteolytic processing of 
the murine norovirus nonstructural polyprotein in infected cells. J Virol 80:7816-7831. 
10. McFadden N, Bailey D, Carrara G, Benson A, Chaudhry Y, Shortland A, Heeney J, 
Yarovinsky F, Simmonds P, Macdonald A, Goodfellow I. 2011. Norovirus regulation 
of the innate immune response and apoptosis occurs via the product of the alternative 
open reading frame 4. PLoS Pathog 7:e1002413. 
11. Baker ES, Luckner SR, Krause KL, Lambden PR, Clarke IN, Ward VK. 2012. 
Inherent structural disorder and dimerisation of murine norovirus NS1-2 protein. PLoS 
ONE 7:e30534. 
12. Borin BN, Tang W, Nice TJ, McCune BT, Virgin HW, Krezel AM. 2013. Murine 
norovirus protein NS1/2 aspartate to glutamate mutation, sufficient for persistence, 
reorients side chain of surface exposed tryptophan within a novel structured domain. 
Proteins doi:10.1002/prot.24484. 
100 
 
13. Nice TJ, Strong DW, McCune BT, Pohl CS, Virgin HW. 2013. A single-amino-acid 
change in murine norovirus NS1/2 is sufficient for colonic tropism and persistence. J 
Virol 87:327-334. 
14. Anantharaman V, Aravind L. 2003. Evolutionary history, structural features and 
biochemical diversity of the NlpC/P60 superfamily of enzymes. GenomeBiol 4:R11. 
15. Ettayebi K, Hardy ME. 2003. Norwalk virus nonstructural protein p48 forms a complex 
with the SNARE regulator VAP-A and prevents cell surface expression of vesicular 
stomatitis virus G protein. J Virol 77:11790-11797. 
16. Fernandez-Vega V, Sosnovtsev SV, Belliot G, King AD, Mitra T, Gorbalenya A, 
Green KY. 2004. Norwalk virus N-terminal nonstructural protein is associated with 
disassembly of the Golgi complex in transfected cells. J Virol 78:4827-4837. 
17. Lev S, Ben Halevy D, Peretti D, Dahan N. 2008. The VAP protein family: from cellular 
functions to motor neuron disease. Trends Cell Biol 18:282-290. 
18. Skehel PA, Martin KC, Kandel ER, Bartsch D. 1995. A VAMP-binding protein from 
Aplysia required for neurotransmitter release. Science 269:1580-1583. 
19. Weir ML, Klip A, Trimble WS. 1998. Identification of a human homologue of the 
vesicle-associated membrane protein (VAMP)-associated protein of 33 kDa (VAP-33): a 
broadly expressed protein that binds to VAMP. Biochem J 333 ( Pt 2):247-251. 
20. Weir ML, Xie H, Klip A, Trimble WS. 2001. VAP-A binds promiscuously to both v- 
and tSNAREs. Biochem Biophys Res Commun 286:616-621. 
21. Alpy F, Rousseau A, Schwab Y, Legueux F, Stoll I, Wendling C, Spiegelhalter C, 
Kessler P, Mathelin C, Rio MC, Levine TP, Tomasetto C. 2013. STARD3 or 
STARD3NL and VAP form a novel molecular tether between late endosomes and the 
ER. J Cell Sci 126:5500-5512. 
22. Loewen CJ, Roy A, Levine TP. 2003. A conserved ER targeting motif in three families 
of lipid binding proteins and in Opi1p binds VAP. EMBO J 22:2025-2035. 
23. Wyles JP, McMaster CR, Ridgway ND. 2002. Vesicle-associated membrane protein-
associated protein-A (VAP-A) interacts with the oxysterol-binding protein to modify 
export from the endoplasmic reticulum. J Biol Chem 277:29908-29918. 
24. Kumagai K, Kawano M, Shinkai-Ouchi F, Nishijima M, Hanada K. 2007. 
Interorganelle trafficking of ceramide is regulated by phosphorylation-dependent 
cooperativity between the PH and START domains of CERT. J Biol Chem 282:17758-
17766. 
101 
 
25. Kawano M, Kumagai K, Nishijima M, Hanada K. 2006. Efficient trafficking of 
ceramide from the endoplasmic reticulum to the Golgi apparatus requires a VAMP-
associated protein-interacting FFAT motif of CERT. J Biol Chem 281:30279-30288. 
26. Furuita K, Jee J, Fukada H, Mishima M, Kojima C. 2010. Electrostatic interaction 
between oxysterol-binding protein and VAMP-associated protein A revealed by NMR 
and mutagenesis studies. J Biol Chem 285:12961-12970. 
27. Mikitova V, Levine TP. 2012. Analysis of the key elements of FFAT-like motifs 
identifies new proteins that potentially bind VAP on the ER, including two AKAPs and 
FAPP2. PLoS One 7:e30455. 
28. Kaiser SE, Brickner JH, Reilein AR, Fenn TD, Walter P, Brunger AT. 2005. 
Structural basis of FFAT motif-mediated ER targeting. Structure 13:1035-1045. 
29. Loewen CJ, Levine TP. 2005. A highly conserved binding site in vesicle-associated 
membrane protein-associated protein (VAP) for the FFAT motif of lipid-binding 
proteins. J Biol Chem 280:14097-14104. 
30. Tu H, Gao L, Shi ST, Taylor DR, Yang T, Mircheff AK, Wen Y, Gorbalenya AE, 
Hwang SB, Lai MM. 1999. Hepatitis C virus RNA polymerase and NS5A complex with 
a SNARE-like protein. Virology 263:30-41. 
31. Evans MJ, Rice CM, Goff SP. 2004. Phosphorylation of hepatitis C virus nonstructural 
protein 5A modulates its protein interactions and viral RNA replication. Proc Natl Acad 
Sci U S A 101:13038-13043. 
32. Roulin PS, Lotzerich M, Torta F, Tanner LB, van Kuppeveld FJ, Wenk MR, 
Greber UF. 2014. Rhinovirus uses a phosphatidylinositol 4-phosphate/cholesterol 
counter-current for the formation of replication compartments at the ER-Golgi interface. 
Cell Host Microbe 16:677-690. 
33. Barajas D, Xu K, de Castro Martin IF, Sasvari Z, Brandizzi F, Risco C, Nagy PD. 
2014. Co-opted oxysterol-binding ORP and VAP proteins channel sterols to RNA virus 
replication sites via membrane contact sites. PLoS Pathog 10:e1004388. 
34. Barajas D, Xu K, Sharma M, Wu CY, Nagy PD. 2014. Tombusviruses upregulate 
phospholipid biosynthesis via interaction between p33 replication protein and yeast lipid 
sensor proteins during virus replication in yeast. Virology 471-473:72-80. 
35. Elwell CA, Jiang S, Kim JH, Lee A, Wittmann T, Hanada K, Melancon P, Engel JN. 
2011. Chlamydia trachomatis co-opts GBF1 and CERT to acquire host sphingomyelin for 
distinct roles during intracellular development. PLoS Pathog 7:e1002198. 
102 
 
36. Derre I, Swiss R, Agaisse H. 2011. The lipid transfer protein CERT interacts with the 
Chlamydia inclusion protein IncD and participates to ER-Chlamydia inclusion membrane 
contact sites. PLoS Pathog 7:e1002092. 
37. Gao L, Aizaki H, He JW, Lai MM. 2004. Interactions between viral nonstructural 
proteins and host protein hVAP-33 mediate the formation of hepatitis C virus RNA 
replication complex on lipid raft. J Virol 78:3480-3488. 
38. Berger KL, Randall G. 2009. Potential roles for cellular cofactors in hepatitis C virus 
replication complex formation. Commun Integr Biol 2:471-473. 
39. Amini-Bavil-Olyaee S, Choi YJ, Lee JH, Shi M, Huang IC, Farzan M, Jung JU. 
2013. The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to 
block viral entry. Cell Host Microbe 13:452-464. 
40. Wang S, Wu X, Pan T, Song W, Wang Y, Zhang F, Yuan Z. 2012. Viperin inhibits 
hepatitis C virus replication by interfering with binding of NS5A to host protein hVAP-
33. J Gen Virol 93:83-92. 
41. Helbig KJ, Eyre NS, Yip E, Narayana S, Li K, Fiches G, McCartney EM, Jangra 
RK, Lemon SM, Beard MR. 2011. The antiviral protein viperin inhibits hepatitis C 
virus replication via interaction with nonstructural protein 5A. Hepatology 54:1506-1517. 
42. Rocha N, Kuijl C, van der Kant R, Janssen L, Houben D, Janssen H, Zwart W, 
Neefjes J. 2009. Cholesterol sensor ORP1L contacts the ER protein VAP to control 
Rab7-RILP-p150 Glued and late endosome positioning. J Cell Biol 185:1209-1225. 
43. Perry JW, Wobus CE. 2010. Endocytosis of murine norovirus 1 into murine 
macrophages is dependent on dynamin II and cholesterol. J Virol 84:6163-6176. 
44. Gerondopoulos A, Jackson T, Monaghan P, Doyle N, Roberts LO. 2010. Murine 
norovirus-1 cell entry is mediated through a non-clathrin-, non-caveolae-, dynamin- and 
cholesterol-dependent pathway. J Gen Virol 91:1428-1438. 
45. Shivanna V, Kim Y, Chang KO. 2015. Ceramide formation mediated by acid 
sphingomyelinase facilitates endosomal escape of caliciviruses. Virology 483:218-228. 
46. Vashist S, Urena L, Goodfellow I. 2012. Development of a strand specific real-time 
RT-qPCR assay for the detection and quantitation of murine norovirus RNA. J Virol 
Methods 184:69-76. 
47. Thorne L, Bailey D, Goodfellow I. 2012. High-resolution functional profiling of the 
norovirus genome. J Virol 86:11441-11456. 
103 
 
48. Nishimura Y, Hayashi M, Inada H, Tanaka T. 1999. Molecular cloning and 
characterization of mammalian homologues of vesicle-associated membrane protein-
associated (VAMP-associated) proteins. Biochem Biophys Res Commun 254:21-26. 
49. Hyde JL, Sosnovtsev SV, Green KY, Wobus C, Virgin HW, Mackenzie JM. 2009. 
Mouse norovirus replication is associated with virus-induced vesicle clusters originating 
from membranes derived from the secretory pathway. J Virol 83:9709-9719. 
50. Borin BN, Tang W, Nice TJ, McCune BT, Virgin HW, Krezel AM. 2014. Murine 
norovirus protein NS1/2 aspartate to glutamate mutation, sufficient for persistence, 
reorients side chain of surface exposed tryptophan within a novel structured domain. 
Proteins 82:1200-1209. 
51. Hagai T, Azia A, Babu MM, Andino R. 2014. Use of host-like peptide motifs in viral 
proteins is a prevalent strategy in host-virus interactions. Cell Rep 7:1729-1739. 
52. Hyde JL, Mackenzie JM. 2010. Subcellular localization of the MNV-1 ORF1 proteins 
and their potential roles in the formation of the MNV-1 replication complex. Virology 
406:138-148. 
53. Nikawa J, Murakami A, Esumi E, Hosaka K. 1995. Cloning and sequence of the SCS2 
gene, which can suppress the defect of INO1 expression in an inositol auxotrophic mutant 
of Saccharomyces cerevisiae. J Biochem 118:39-45. 
54. Kagiwada S, Zen R. 2003. Role of the yeast VAP homolog, Scs2p, in INO1 expression 
and phospholipid metabolism. J Biochem 133:515-522. 
55. Loewen CJ, Young BP, Tavassoli S, Levine TP. 2007. Inheritance of cortical ER in 
yeast is required for normal septin organization. J Cell Biol 179:467-483. 
56. Weber-Boyvat M, Kentala H, Peranen J, Olkkonen VM. 2015. Ligand-dependent 
localization and function of ORP-VAP complexes at membrane contact sites. Cell Mol 
Life Sci 72:1967-1987. 
57. Mesmin B, Bigay J, Moser von Filseck J, Lacas-Gervais S, Drin G, Antonny B. 2013. 
A four-step cycle driven by PI(4)P hydrolysis directs sterol/PI(4)P exchange by the ER-
Golgi tether OSBP. Cell 155:830-843. 
58. Wakana Y, Kotake R, Oyama N, Murate M, Kobayashi T, Arasaki K, Inoue H, 
Tagaya M. 2015. CARTS biogenesis requires VAP-lipid transfer protein complexes 
functioning at the endoplasmic reticulum-Golgi interface. Mol Biol Cell 26:4686-4699. 
59. Kumagai K, Kawano-Kawada M, Hanada K. 2014. Phosphoregulation of the ceramide 
transport protein CERT at serine 315 in the interaction with VAMP-associated protein 
(VAP) for inter-organelle trafficking of ceramide in mammalian cells. J Biol Chem 
289:10748-10760. 
104 
 
60. Liu H, Naismith JH. 2008. An efficient one-step site-directed deletion, insertion, single 
and multiple-site plasmid mutagenesis protocol. BMC Biotechnol 8:91. 
61. Chaudhry Y, Skinner MA, Goodfellow IG. 2007. Recovery of genetically defined 
murine norovirus in tissue culture by using a fowlpox virus expressing T7 RNA 
polymerase. JGenVirol 88:2091-2100. 
62. Hwang S, Alhatlani B, Arias A, Caddy SL, Christodoulou C, Cunha JB, Emmott E, 
Gonzalez-Hernandez M, Kolawole A, Lu J, Rippinger C, Sorgeloos F, Thorne L, 
Vashist S, Goodfellow I, Wobus CE. 2014. Murine norovirus: propagation, 
quantification, and genetic manipulation. Curr Protoc Microbiol 33:15K 12 11-61. 
63. Greninger AL, Knudsen GM, Betegon M, Burlingame AL, DeRisi JL. 2013. ACBD3 
interaction with TBC1 domain 22 protein is differentially affected by enteroviral and 
kobuviral 3A protein binding. MBio 4:e00098-00013. 
64. Parikh BA, Beckman DL, Patel SJ, White JM, Yokoyama WM. 2015. Detailed 
phenotypic and molecular analyses of genetically modified mice generated by CRISPR-
Cas9-mediated editing. PLoS One 10:e0116484. 
65. Gaudet M, Fara AG, Beritognolo I, Sabatti M. 2009. Allele-specific PCR in SNP 
genotyping. Methods Mol Biol 578:415-424. 
66. Lee W, Tonelli M, Markley JL. 2015. NMRFAM-SPARKY: enhanced software for 
biomolecular NMR spectroscopy. Bioinformatics 31:1325-1327. 
67. Kearse M, Moir R, Wilson A, Stones-Havas S, Cheung M, Sturrock S, Buxton S, 
Cooper A, Markowitz S, Duran C, Thierer T, Ashton B, Meintjes P, Drummond A. 
2012. Geneious Basic: an integrated and extendable desktop software platform for the 
organization and analysis of sequence data. Bioinformatics 28:1647-1649. 
68. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, 
Ferrin TE. 2004. UCSF Chimera--a visualization system for exploratory research and 
analysis. J Comput Chem 25:1605-1612. 
 
  
105 
 
3.8 Figures 
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Figure 3.1. MNoV replication in Vapa
-/- 
cells is diminished.  
(A) Alignment of genomic sequence and translation for two Vapa edited RAW264.7 cell lines 
with WT Vapa
+/+
 (NM_013933) (top), showing both mutant alleles for each cell line. Numbering 
relative to transcript start. 
(B) Western blot against VAPA and ACTIN (loading control) in WT and Vapa
-/-
 cell lines. 
107 
 
(C) Murine norovirus strains-CW3 (top) or CR6 (bottom) growth in Vapa
-/-
 and Vapa
+/+
 cell 
lines, MOI 0.05 (left) or 5.0 (right) PFU/ml. Repeated measure one-way ANOVA, Dunnett post-
test. 
(D) Cell viability of MNoV infected Vapa
-/-
 and Vapa
+/+
 cell lines determined by live/dead 
fixable stain followed by FACS, relative to WT mock infected.  
(E) Representative infection frequency of MNoV-CW3 in Vapa
-/-
 cells, measured by intracellular 
FACS of NS1/2, 18 hours post infection. 
(F) Same as (E), combined experiments, repeated measure two-way ANOVA, Dunnett post-test, 
n=3. 
(G) Infection frequency of BV2-Cas9 cells transduced with one of three lentiviruses expressing 
unique sgRNA against Vapa. MOI 0.1, n=3.  
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Figure 3.2. Reconstitution of VAPA expression in Vapa
-/-
 cells rescues MNoV infectivity.  
(A) Western blot of Vapa
+/+
 or Vapa
-/-
 cell lines lentivirally transduced with FLAG-GFP or 
FLAG-Vapa, GAPDH loading control.  
(B) MNoV-CW3 growth 18hpi in Vapa or GFP in transduced cells as in (A). Two-way 
ANOVA, Sidak post-test. 
(C) MNoV infection frequency in FLAG-Vapa or FLAG-GFP transduced cells as in (A), two-
way ANOVA Sidak post-test, n=9. 
(D) Relative MNoV infectivity in FLAG-Vapa transduced cells, relative to FLAG-GFP 
transduced cells for each cell line. Two-tailed t-test relative to H0=1.  
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Figure 3.3. Vapa
-/-
 mice are embryonic lethal. 
(A) Alignment of two Vapa mutant mouse lines generated by electroporating embryonic stem 
cells with Cas9 and gRNA targeting Vapa. Note mutant line 1 has splice junction deleted, and 
mutant line 2 has single base pair insertion. Numbering relative to transcript start.  
(B) Number of live pups of indicated genotypes from heterozygote crosses. 
(C) Number of day 14 embryos of indicated genotype. Embryonic day 14 embryos were isolated 
from heterozygote crosses and genotyped, four litters total. Undetermined refers to samples for 
which PCR failed to amplify. 
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Figure 3.4. MNoV replication in RAW264.7-Vapa
-/-
 cells is impaired early in viral life cycle.  
(A) Western blot of NS1/2 in Vapa
+/+
 and Vapa
-/-
 (3A11) cell lines, MOI 5. Right, combined 
densitometry from multiple experiments performed on film exposures for each time point within 
linear range of assay (n=2-4), (unpaired t-test, means compared to HO=1). 
(B) NS1/2 western blot after electroporating vRNA into Vapa
+/+
 and Vapa
-/-
 cells 
(representative, n=3-5). Middle, Vapa
+/+ 
and Vapa
-/-
 cells are transfected equivalently with 
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pMAX-GFP. Right, combined densitometry as in (A) (n=3-5).  
(C) Viral strand-specific quantitative PCR for negative strand (left) and positive strand (right) 
over time in infected Vapa
+/+
 and Vapa
-/-
 cells, MOI 5 (n=3, two-way ANOVA).  
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Figure 3.5. NS1/2 interaction with VAPA is conserved among norovirus strains.  
(A) Representative immunoprecipitation of Flag-NS1/2-HNoV (GI), -MNoV (CR6) with HA-
VAPA or HA-NS4 (n=3). 
(B) M2H interaction of NS1/2
GI
, NS1/2
MNoV
 (CR6 and CW3), OSBP, and VAPA with VAPA, as 
well as NS1/2
CR6
 with VAPB (one-way ANOVA, Dunnett; fold change on right).  
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Figure 3.6. NS1/2 interacts with VAPA during infection.  
(A) Engineering infectious FLAG-tagged MNoV. The FLAG epitope tag was inserted into sites 
in NS1/2 (top) or in NS4 (bottom) (47). 
(B) Growth characterization of the NS1/2-FLAG (left) and NS4-FLAG (right) viruses. A 
multistep growth curve was performed by infecting BV2 cells with either virus at an MOI of 
0.01 TCID50/cell. Virus was harvested at the specified time points and viral titer determined by 
TCID50. Two-way ANOVA, Bonferroni post-test compared WT and FLAG-insertion virus at 
each time point, n=3. LOD: limit of detection, 11.2 TCID50/ml. 
(C) Immunofluorescence in BV2 cells infected with NS1/2-FLAG, NS4-FLAG or WT virus, 
labeled on left of panels, MOI 5 TCID50/cell, 12hpi. Samples were stained for FLAG, NS7, and 
DAPI, labeled on top of panels.  
(D) BV2 cells were infected with NS1/2-FLAG or NS4-FLAG MNV for 8 hours, MOI 10 
TCID50/cell. FLAG pulldowns were performed on lysates, and immunoblotted with the specified 
antibodies. 
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Figure 3.7. NS1/2 binds FFAT-interacting residues in MSP domain of VAPA.  
(A) M2H interaction of NS1/2
MNoV
 with VAPA mutants.  
(B) MNoV infectivity in Vapa
-/-
 cells transduced with lentivirus expressing GFP, VAPA, and 
VAPA mutants. Showing fold change %NS1/2+ cells in VAPA (or VAPA mutant) transduced 
cells over GFP transduced cells.  
(C) Chemical shift perturbations of amide resonances upon unlabeled-NS1
CW3
 titration into 
15
N-
labeled VAPA MSP. Horizontal broken line represents threshold. 
(D) M2H analysis of additional single residue mutant VAPA. Underline=residues interacting 
with FFAT as shown by NMR and crystal structure (26, 28).  
(E) Murine VAPA MSP domain (PDB: 2CRI). Pink residues disrupted NS1/2-VAPA interaction 
in M2H when mutated; mutations in cyan-colored residues did not disrupt interaction. 
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Figure 3.8. Poorly conserved NS1 domain within NS1/2
MNoV
 interacts with VAPA.  
(A) Alignment of NS1/2 from representative strains from each norovirus genogroup.  
(B) M2H of full length or truncations of NS1/2
MNoV
 (CR6) with VAPA.  
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Figure 3.9. N-terminal segment of NS1-MNoV interacts with VAPA.  
(A) A portion of superimposed 
1
H-
15
N HSQC spectra of NS1
CW3
 with increasing levels of 
VAPA. Molar ratio NS1:VAPA: 1:0.0, red; 1:0.3, orange; 1:0.6, yellow; 1:1.2, green; 1:2.6, 
cyan; 1:4.9, blue. Assignments and peak positions are shown for free NS1 sample. Insert shows 
structure of NS1 28-114 (PDB: 2MCH), with core VAPA interacting residues labeled in blue. 
(B) Chemical shift perturbations of amide resonances upon unlabeled-VAPA titration into 
15
N-
labeled NS1-CR6, CW3, CR6
M48G
, CW3
T49G
, and CW3
E52K
. Horizontal broken line is threshold.  
(C) Sequence logo of FFAT-like amino acid sequence of NS1/2 derived from BLAST alignment 
(Supplemental Figure 6). Font size for each amino acid proportional to percent conservation at 
each position.  
(D) M2H interaction with NS1/2 substitutions (NS1/2: bait, VAPA: prey). Residues 69, 121, and 
131 are not predicted to interact with VAPA. Purple residues same as (C). 
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Figure 3.10.BLAST alignment of NS1/2 sequence resembling FFAT.  
Bottom two sequences are from Rat Norovirus, the most divergent NS1/2 sequence within GV.   
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Figure 3.11. NS1/2 interaction with VAPA enhances recovery of MNoV from infectious 
clones.  
(A) Recovery titers of mutants of MNoV strain pCR6. Showing passage one titers (n=7-20). 
Virus was quantified by plaque assay. Purple text indicates less conserved residue as in Fig 3.9C. 
(B) Same as (A) but using MNoV-pCW3. 
(C) Summary of interaction of NS1/2 mutants with Vapa in M2H, and recovery of virus from 
infectious clones for CW3 and CR6 NS1/2 mutants. Purple text same as (A). 
(D) Solution structure of NS1-MNoV with viable (black) and non-viable (red) mutants. 
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Chapter 4:  
Summary and Future Directions 
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4.1 Summary 
The unifying theme in this dissertation is the molecular mechanisms of NoV replication in 
mice and cells. We directed the work to the following questions: 1) what are the viral 
mechanisms to establish persistent infection in mice, and 2) what is the function of NoV protein 
NS1/2? The work presented herein described the importance of the viral molecule NS1/2 during 
persistent infection in mice and viral replication in cell culture. VP1 was an important 
determinant of tropism in vivo and ex vivo for different MNoV strains. Lastly, this work 
uncovered a role for the host molecule VAPA during MNoV infection.  
In Chapter 2, we found NS1/2 and VP1 are major determinants of persistence and 
tropism. The NS1 domain of the NS1/2 protein from MNoV strain CR6 conferred persistence 
and colonic tropism on CW3. This mapped to a single amino acid change within NS1, D94E, 
which conferred persistence on CW3. While E94D did not prevent CR6 persistence, other 
mutants within NS1 domain did not persist, including mutations that disrupt proteolytic cleavage 
of NS1 and NS2 domains. Viruses with NS1/2 mutants replicated equivalently to WT virus in 
cell culture, but many NS1/2 mutant viruses had delayed release of virus from cells. This work 
establishes important functions for NS1/2 in establishing persistent infection in mice and viral 
replication in cell culture. NS1/2 has hitherto been poorly characterized, and these observations 
expand what is known about NS1/2.  
VP1
CW3
 conferred splenic tropism on CR6, and VP1
CR6
 prevented splenic tropism on CW3. 
Furthermore, viruses with VP1
CW3
 grew robustly in BMDMs in cell culture while viruses with 
VP1
CR6
 grew poorly. These studies 1) strengthen a role for VP1 as a determinant of tropism and 
2) highlight a role for cellular tropism as a mechanism for phenotypic differences among MNoV 
strains.  
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In Chapter 3, we found MNoV replication is enhanced by the host protein VAPA. Loss of 
VAPA expression led to a delay in production of NS1/2 very early in infection. VAPA enhanced 
viral infection in part by directly interacting with NS1/2. The sequence in NS1/2 that interacted 
with VAPA closely resembled the FFAT host motif that mediates host protein interaction with 
VAPA. Furthermore, the mechanism for interaction with VAPA by NS1/2 was similar to FFAT 
interaction with VAPA. This represents the first detailed cellular mechanism described for 
NS1/2. This is also the first reported example of microbial mimicry of FFAT motifs.  
 
4.2 Future Directions 
 
4.2.1 Persistence  
NS1/2
CR6
 conferred colonic tropism and persistent shedding of MNoV in mice but the 
functions of NS1/2 during infection is unknown. NS1/2 variants associated with persistence are 
structurally different in the NS1 domain, and how this alters NS1/2 functionally is an important 
question. Because both NS1/2
CR6
 and NS1/2
CW3
 equivalently bind VAPA, and are similarly 
affected by loss of VAPA expression, it is unlikely that VAPA alone is related to persistence. 
Therefore, more fundamental information about the function of NS1/2 is required to assess how 
this conformational change affects persistence. One approach will be to determine what other 
proteins NS1/2 interact with during infection using NS1/2-FLAG tagged virus for different 
MNoV strains, and performing immunoprecipitations. This approach was validated herein, and 
promises to be a powerful strategy to discover additional NS1/2 interacting proteins during 
infection.  
While this work did not focus on innate immune responses, emerging studies have identified 
connections among persistence, tropism, and innate immunity for MNoV. Therefore, innate 
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immunity against MNoV is a key future direction to understand persistence and tropism. MNoV 
is controlled by type I and type III interferons (IFN) in systemic and intestinal tissues, 
respectively (1, 2). VP1
CW3
 is linked to induction of type III IFN, IFNλ, which correlates with 
clearance of MNoV from mice (1). It is nevertheless unclear if VP1 is the sole determinant of 
IFNλ sensitivity or if NS1/2 also modulates MNoV sensitivity to the functions of IFNλ. Further 
studies are needed to uncover how VP1 regulates IFNλ induction and any potential role for 
NS1/2 in IFN induction, signaling, or ISG function. For example, what cell subsets induce IFNλ 
during infection? Does VP1 confer tropism in those subsets? Will pCR6-NS1
CW3
 (and other non-
persistent pCR6-NS1/2 mutants) persist in Ifnlr
-/-
 mice? Studies to address these questions are 
ongoing.  
Key to these studies is identifying a cell type in which CW3 and CR6 differentially induce 
and are differentially sensitive to IFNλ. An interesting nuance to these studies is that IFNλ did 
not affect viral growth in myeloid cells ex vivo (Tim Nice personal communication, data not 
shown) and does not act on myeloid cells in vivo, but rather on intestinal epithelial cells (3). This 
is significant because current evidence argues that NoV replicates in myeloid cells but not 
epithelial cells. How is MNoV regulated by IFNλ when IFNλ does not directly act on infected 
cells? Several non-mutually exclusive possibilities may reconcile this conundrum: 1) MNoV 
does replicate in epithelial cell; 2) there is cross-talk between infected myeloid cells producing 
IFNλ and IFNλ responsive epithelial cells that restricts infection; 3) epithelial cells can restrict 
virus without being infected, such as by regulating barrier integrity. Germane to the first 
possibility is the need to identify the cell type MNoV infects in wild-type mice, as discussed 
below. Myeloid-epithelial cell cross talk is important during infection (4); to determine if this 
occurs during MNoV infection, we can infect macrophages in the presence of intestinal epithelial 
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cells using trans-wells, then measure viral growth. Alternatively, it would be interesting to treat 
epithelial cells with IFNλ, harvest the conditioned media, and treat infected myeloid cells with 
this conditioned media. Biochemical fractionation of the conditioned media could help determine 
which factor(s) contribute to MNoV control. The development of mice with Ifnlr deleted in 
specific cell types will corroborate with these studies. Lastly, IFNλ is known to affect barrier in 
different tissues (5), and this could be assessed in the intestine during infection, in Ifnlr
-/-
 mice, 
and upon IFNλ treatment using a tissue diffusible dye that variably diffuses across the intestine 
dependent upon barrier integrity.  
As sequence outside NS1 for either CW3 or CR6 were not necessary for persistence, and E94 
was not necessary for CR6 to persist, we reasoned other residues within NS1 were necessary for 
persistence. In preliminary work, mutations that disrupted caspase cleavage sites separating NS1 
and NS2 domains (6) did not persist in mice (data not shown). Furthermore, products correlating 
with NS1 and NS2 sizes accumulate during infection MNoV infection of cell lines. These 
observations argue NS1 and NS2 are cleaved during infection and that cleavage is necessary to 
establish persistent infection. Further studies are needed to determine the mechanism of 
cleavage, if it is spatiotemporally regulated, and the importance of cleavage in cell culture as 
well as mice. It is particularly interesting if NS1/2 is cleaved by caspases, as this may provide a 
way for MNoV to sense cellular responses to infection and subsequently alter replication or 
antagonize innate immune responses. Caspase activation and cleavage of viral proteins is 
important in other viral systems (reviewed in (7)), but this observation could provide novel 
significance for caspase regulation of viral proteins. To determine the mechanism of cleavage, 
MNoV infected cells can be treated with pan-caspase inhibitors then monitor NS1/2 cleavage. To 
test a role for caspases on replication, virus titers can also be monitored during treatment. 
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Furthermore, NS1/2 cleavage during infection with MNoV caspase-cleavage-site mutants will 
demonstrate which sites are targeted during infection. Detailed growth curves are needed to 
assess the effect of these mutants on viral growth. Preliminary studies using Caspase3
-/-
 mice did 
not show any effect on MNoV replication or persistence (data not shown), but this may be 
related to extensive redundancy of caspases. Therefore, to demonstrate a role for caspase 
activation in persistent MNoV infection, mice can be treated with pan-caspase inhibitors and 
viral shedding monitored. If it is validated that NS1 are cleaved, the function of the divided 
proteins will be interesting to pursue. It is possible that NS1 function(s) during persistent viral 
infection are independent of NS2.  
4.2.2 Tropism in vivo 
The work herein provides new evidence for viral factors that contribute to tissue tropism, 
NS1/2 and VP1. Furthermore, the assays used herein (qRT-PCR) did not differentiate from the 
presence of virus and replicating virus. Detecting replicating virus may require development of 
techniques that detect viral antigens or products only present during viral replication, such as 
detection of minus strand RNA, or viral non-structural proteins. Nevertheless, a clear challenge 
to detecting persistent virus infection is there are low levels of viral antigens across the intestine. 
This may be the consequence of infrequent infection with high level of antigen/virion 
production, or frequent infection with low level of antigen/virion production. In the first case, 
higher throughput assays are needed to analyze cells in bulk, such as FACS or whole organ 
immunohistochemistry. In the second case, methods that are more sensitive are needed to detect 
viral antigen. Single molecule FISH assays coupled with FACS, in situ PCR, and novel genetic 
viral reporters, may help with this hurdle. Genetically overexpressing or deleting host factors 
regulating NoV infection in specific cell types will provide evidence for the cell types involved 
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in infection (pathogenesis, immune responses, persistence, etc.). These factors may include 
STAT1, IFNLR, IFNAR, HSP90, and VAPA. For example, CD11c-Ifnar
-/-
 and LyzM-Ifnar
-/-
, but 
not Villin-Ifnar
-/-
 mice, did not clear acute CW3 infection (8, 9). This indicates that Type I IFN 
signaling in CD11c+ or LyzM+ cells is necessary to clear CW3 infection. This was likely due to 
unrestrained replication of CW3 in dendritic cells and macrophages and occurred in the face of 
an adaptive immune response typical for WT animals, thus strengthening the evidence that 
MNoV replicates in dendritic cells and macrophages in vivo. More studies like this will be 
important. Nevertheless, direct detection of virus will be required to definitively conclude the 
cell type NoV infects. 
As current assays are insufficiently sensitive to directly detect virus, it will be difficult to 
directly assess the question how NS1/2 and VP1 contribute to tropism. Relying on growth of 
virus in ex vivo cells may help overcome this hurdle. In this work, we presented that CW3 and 
CR6 replicate differently in BMDMs ex vivo. This difference may reflect a different tropism for 
different macrophage subsets in vivo. Performing MNoV growth curves in macrophages and 
dendritic cell subsets from intestines, spleens, etc., can help further refine cellular tropism. 
Additionally, it will be interesting to differentiate cells into different macrophage and dendritic 
cell subsets to determine if differentiation or activation state determines cellular tropism for viral 
strains. Subsequently performing gene expression analysis to identify differentially expressed 
genes may help correlate host pathways associated with CR6 or CW3 infection. Further mapping 
of viral determinants to replicate in these cell subsets may correlate in vivo phenotypes such as 
persistence with these host pathways. Therefore, it may be possible to use different cell types to 
help identify host factors involved in regulating persistent infection.  
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Growth in BMDMs mapped to VP1
CW3
. While VP1 can enhance viral RNA synthesis 
(10, 11), this is mediated by the shell domain that had no influence on viral replication in 
BMDMs. VP1, and particularly the protruding domain, is the major determinant for cellular 
tropism (12). These observations together suggest CR6 and CW3 may utilize different cellular 
factors to mediate entry into the cell. Recent observations that CD300lf is a protein receptor for 
MNoV (in press), but CR6 and CW3 similarly require CD300lf. Two possibilities to explain 
differences in BMDM growth are 1) there are other co-factors uniquely used by CR6 or CW3 in 
BMDMs, or 2) pathways downstream of binding are different. First, testing if CR6 and CW3 are 
recovered equivalently when added to BMDMs at 4°C will assess if these strains bind BMDMs 
differently. Second, MNoV-1 entry in BMDMs is dependent on dynamin and cholesterol (13, 
14), but these studies did not analyze other strains of MNoV. Repeating these studies with CR6 
and CW3 using 1) pharmacological inhibitors of endocytosis pathways and cholesterol 
trafficking, 2) knockouts of GTPases controlling endosomal trafficking, and 3) detailed time-
course imaging of MNoV genomes with single-molecule FISH and subcellular markers, will 
assess if known MNoV entry pathways are similar between CR6 and CW3.  
 
4.2.3 VAPA 
This work establishes VAPA as a pro-MNoV factor. In this work, we did not use any 
functional systems for HNoV, which recently is becoming a more tractable system (15, 16) and 
may be assessed in the near future. What function VAPA plays during NoV function, and how 
broadly VAPA is used in other microbial infections are important questions.  
Determining how VAPA enhances MNoV infection is a key aim to better understand the 
molecular and cellular requirements for efficient MNoV replication. Furthermore, it will be 
central to understanding the function of NS1/2 during infection. VAPA could serve at least two 
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non-mutually exclusive functions for MNoV: 1) VAPA enhances NS1/2 function and 2) VAPA 
is needed for NS1/2 to manipulate VAPA-client protein(s) function(s).  
First, VAPA may regulate NS1/2 function. VAPA may influence NS1/2 subcellular 
localization. NS1/2 is the first protein translated from the MNoV genome, and binds other viral 
factors (17). Therefore, where NS1/2 localizes may influence the function of other viral proteins 
and subsequently virus replication. NS1/2 localizes to the ER (18), the major site of VAPA 
localization, but it is unknown if VAPA influences where NS1/2 localizes, either directly or 
indirectly. While ectopically expressed NS1/2 colocalized with overexpressed VAPA in 293T 
cells (data not shown), this study must be repeated during infection in Vapa
+/+
 cells. Assessing if 
NS1/2 is mislocalized using subcellular markers against ER in 1) Vapa
-/-
 cells, 2) reconstituted 
Vapa
-/-
 cells with VAPA mutants that do not interact with NS1/2, and 3) MNoV-NS1/2 mutant 
viruses that disrupt VAPA interaction will determine if NS1/2-VAPA interaction is necessary for 
NS1/2 subcellular localization. Additionally, time courses analyzing VAPA localization with ER 
and other subcellular markers during the course of infection will test the hypothesis that NS1/2 
redistributes VAPA during infection. These initial studies should be done using confocal 
microscopy. Because some VAPA-associated cellular structures are only detectable via high-
resolution techniques, follow up studies should be done with EM and STORM.  
VAPA may also affect the function of NS1/2 by regulating its function. Determining 
additional function(s) of NS1/2 is a key goal to learn if VAPA or other host factors regulate 
NS1/2. A simple yet challenging goal will be to discover the function of the NS2 domain. By 
sequence comparison NS2 has a fold found in diverse enzymes. Early structural determinations 
and mutagenesis indicate that NS2 adopts this fold (Krezel, unpublished communication) and the 
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key residues involved in catalysis are necessary for viral infection (unpublished). However, 
definitive proof will require defining the substrates of NS2, a challenging goal.  
Second, NS1/2 may manipulate or coopt VAPA client proteins. In this scenario, NS1/2 turns 
on, off, redirects, or alters the normal function of VAPA client proteins. VAPA client proteins 
have roles in diverse cellular processes, including proteostasis (19-26), non-vesicular lipid 
transfer (27-32), membrane morphology (26, 33, 34), and membrane contacts (26, 30, 32, 35-
37), but it is unknown if any of these processes influence NoV replication. A primary goal is to 
define which client proteins are pro- or antiviral to NoV replication. However, many VAPA 
interacting proteins perform redundant functions, or are otherwise spatiotemporally regulated. 
Therefore, direct studies on these cellular pathways in NoV infection are crucial.  
One mechanism by which NS1/2 could regulate VAPA client protein function is to interact 
competitively with VAPA, thus disrupting physiological localization of client proteins. In this 
model, NS1/2 saturates VAPA interactions globally, locally, or redirects VAPA to subcellular 
locations where it no longer performs its physiological functions. To this end, preliminary 
estimations of NS1/2-VAPA dissociation constant are similar to those published for client 
proteins (Krezel private communication and (38)). One possibility for NS1/2 to outcompete other 
VAPA interactions at physiological levels would be for NS1/2 to have higher local 
concentrations. Regulation of VAPA-client proteins by competition has been observed in two 
settings. First, VAPA interacts competitively with FFAT motifs and either FAF1 or ATF6 that 
may mediate switching between regulating lipid trafficking and ER quality control (22). It is an 
attractive possibility that NS1/2 rewires host proteostatic/lipid dynamics by competitively 
binding VAPA. Second, IFITM3 competitively binds VAPA away from lipid transfer proteins 
(LTPs); this correlates with cholesterol accumulation in endosomes (39). It is unknown if IFITM 
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family members are antagonistic to NoV replication. Given the similar Kd of NS1/2-VAPA as 
LTP-VAPA, NS1/2-VAPA may likewise be susceptible to competition by IFITM3. 
Alternatively, NS1/2 may sequester VAPA into RCs, preventing competition by IFITM3. A 
separate IFN stimulated VAPA-client protein, RSAD2, antagonizes HCV infection by disrupting 
VAPA-NS5a interaction (40, 41). However, preliminary studies in mice did not find an antiviral 
role for RSAD2 against MNoV (Larissa Thackray, private communication). To test these 
hypotheses, biochemical competition assays to test NS1/2-VAPA-client protein interaction can 
be attempted. Furthermore, assessing client protein localization, including OSBP and IFITM3, 
during infection by microscopy will be important.  
In addition to those discussed above, non-vesicular, protein-mediated lipid transfer is the 
primary function of VAPA and the most studied function in relation to microbial infection. 
Particularly, the role of PI4P and cholesterol are important during viral infection. To determine if 
PI4P and cholesterol localize to replication complexes, antibodies and genetic probes can be used 
to stain PI4P, and filipin can be used to stain cholesterol. Small molecules to inhibit PI4K family 
of enzymes can be used to disrupt the formation of PI4P, and itraconazole as well as osw-1 
inhibit the activity of OSBP. Furthermore, knocking out OSBP, PI4K, and VAP-client proteins 
will be critical and simple with the advent of CRISPR-Cas9 genome editing technology.  
VAP proteins make membrane contact sites (MCS) which are associated with the viral 
replication of tombusviruses, a genus of plant viruses. It may be that non-vesicular lipid transfer 
predominately occurs at MCSs. Therefore, establishing a role for lipid transfer proteins and 
lipids during NoV may infer that MCSs are involved in NoV replication. Furthermore, MCSs 
have been technically challenging to study as they are only detectable by careful analysis of 
electron micrographs. Therefore, electron microscopy of cells infected with NoV coupled with 
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high-resolution fluorescent microscopy techniques may facilitate studying MCSs during NoV 
infection. Lastly, ultrastructural reconstructions using EM tomography of infected cells has 
revealed remarkable detail of membrane interactions for a number of viruses (42-44). The study 
of membranes in NoV infection will benefit from EM tomography, albeit they are technically 
difficult to execute. 
Lastly, the intracellular bacteria Chlamydia trachomatis also requires VAP proteins, but also 
encodes a virulence factor IncD that interacts with the VAP-client protein CERT (45, 46). VAP 
and CERT localize with IncD at ER-bacterial inclusion MCSs. At these sites, CERT transfers 
ceramide to the bacterial inclusion that is processed to sphingomyelin and used by the bacteria. 
There are no precedents for viruses requiring CERT. While there is some evidence for a role for 
ceramide in NoV entry into cells (47), it is unknown if CERT, ceramide, or sphingomyelin are 
required for viral replication. Studies looking at the localization of CERT and ceramide, as well 
as knocking out CERT will be informative. 
How broadly among intracellular pathogens is VAPA utilized? Reported VAPA-dependent 
pathogens include positive-sense RNA viruses and intracellular bacteria, and we add NoV to this 
list. Furthermore, the flavivirus West Nile Virus (WNV) had diminished infectivity in Vapa
-/- 
RAW264.7 cells, but viral replication was only diminished relative to Vapa
+/+
 upon IFNb 
treatment (Matthew Gorman, Michael Diamond Lab, personal communication). A dependency 
on VAPA for WNV is unsurprising as WNV is related to HCV and utilizes the ER during 
infection. In contrast, preliminary studies showed diminished replication for lymphocytic 
Choriomeningitis virus (LCMV) in Vapa
-/-
 cells LCMV only upon LPS treatment (Brian 
Sullivan, Oldstone Lab, personal communication). The replication life cycle of LCMV, which 
has an ambisense genome, is much different from currently described VAPA-dependent 
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microbes. Furthermore, the observation that replication was synergistically affected upon IFNβ 
or LPS treatment in Vapa
-/-
 cells may provide additional insight into VAPA function under 
different stimuli. More studies with negative-sense viruses, DNA viruses, and parasites such as 
Toxoplasma will be informative. Of DNA viruses, poxviruses are particularly promising as they 
require extensive membrane rearrangements during replication. Nevertheless, screening a diverse 
set of pathogens with unique replication life-styles under different treatment conditions may 
reveal unique roles of VAPA during infection.  
 
4.2.4 FFAT mimicry 
Mimicry of host molecules and patterns is a pervasive evolutionary outcome for pathogens 
selected to hijack host processes (48). While efforts have been made to predict mimicry on large-
scale (48), detecting structural and/or functional mimics requires validation of individual 
microbial molecules. For VAPA-microbe interactions, microbial mimicry of FFAT motifs is 
previously unreported.  
NS1/2 is the first example of microbial mimicry of FFAT motifs. FFAT motifs tolerate 
variation at many positions (28, 49), are relatively short, and are unstructured in solution, making 
it unsurprising that a rapidly evolving virus could select these sequences. The advantage afforded 
by direct interactions with VAPA and VAPB proteins has been reported for Hepatitis C Virus 
(50, 51), which, in a similar way to many positive RNA viruses, rely on significant levels of 
membrane rearrangement for efficient viral replication. NS1/2 FFAT mimic was most similar N 
and C-terminally to host FFAT sequences. Further analyses of NoV NS1 sequences across 
diverse HNoV strains may further widen the definition of what constitutes a FFAT sequence 
(52).  
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It will be interesting to study how frequently FFAT mimicry occurs among microbes. HCV 
NS5a and NS5b both bind MSP domain in sites partially overlapping FFAT motif binding, yet 
neither protein contains sequences resembling FFAT motifs. This argues HCV evolved a unique 
way to interact with VAP proteins. A rigorous bioinformatic search for microbial FFAT motifs 
will be informative, but nonetheless would likely underrepresent the “VAPome” of microbial-
VAPA interactors.  
Finally, VAPB also interacts with NS1/2, probably through a common mechanism as VAPA. 
VAPA and VAPB demonstrably have overlapping functions, and it is currently unclear what, if 
any, functions are unique to each protein. The observation that Vapb
-/-
 mice are viable but Vapa
-/-
 
mice are embryonic lethal, and that VAPB is linked to Amyotrophic Lateral Sclerosis, but VAPA 
is not, argues there are unique functions or spatiotemporal expression patterns between VAPA 
and VAPB. Nevertheless, VAPA and VAPB possibly have redundant functions during MNoV 
replication. It will be important to test a role for VAPB using VAPB knockout cells and 
VAPA/VAPB double knockout cells, which are currently under development.   
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